var title_f10_58_11168="Simple anal fistula";
var content_f10_58_11168=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F56209&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F56209&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Simple anal fistula",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 351px; height: 203px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This intra-operative photograph shows the primary internal opening and the secondary external opening of the simple anal fistula.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bradley J Champagne, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_58_11168=[""].join("\n");
var outline_f10_58_11168=null;
var title_f10_58_11169="Hepatitis A vaccine: Patient drug information";
var content_f10_58_11169=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Hepatitis A vaccine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/30/44518?source=see_link\">",
"     see \"Hepatitis A vaccine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/43/38581?source=see_link\">",
"     see \"Hepatitis A vaccine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F178838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Havrix&reg;;",
"     </li>",
"     <li>",
"      VAQTA&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F178839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Avaxim&reg;;",
"     </li>",
"     <li>",
"      Avaxim&reg;-Pediatric;",
"     </li>",
"     <li>",
"      HAVRIX&reg;;",
"     </li>",
"     <li>",
"      VAQTA&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt adi-os drugH1Div\" id=\"F10031424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     CDC Information",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Vaccine Information Statements (VIS) are made by the staff of the Centers for Disease Control and Prevention (CDC). Each VIS gives information to properly inform the adult receiving the vaccine or, in the case of a minor, the child's parent or legal representative about the risks and benefits of each vaccine. Before a doctor vaccinates a child or an adult, the provider is required by the National Childhood Vaccine Injury Act to give a copy of the VIS. You can also get foreign language versions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705990",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <a href=\"file://www.immunize.org/vis/vis_hepatitis_a.asp\" target=\"_blank\">",
"        Vaccine Information Statements (VIS)",
"       </a>",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11765 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.172.26-18D72DAC39-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_58_11169=[""].join("\n");
var outline_f10_58_11169=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178838\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178839\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031424\">",
"      CDC Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?43/30/44518?source=related_link\">",
"      Hepatitis A vaccine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/43/38581?source=related_link\">",
"      Hepatitis A vaccine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_58_11170="Aortic root calcification Lat";
var content_f10_58_11170=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F74730&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F74730&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Calcification of the aortic root",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 260px; height: 330px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lateral view of chest x-ray shows calcification at the aortic root (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal lateral chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 252px; height: 368px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Steven Weinberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_58_11170=[""].join("\n");
var outline_f10_58_11170=null;
var title_f10_58_11171="Bronchoscopic laser coagulation";
var content_f10_58_11171=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F81276&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F81276&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Bronchoscopic laser coagulation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 258px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) During rigid bronchoscopic resection, coagulation is obtained using a bare laser fiber and Nd:YAG laser energy at low power density, causing tissue blanching.",
"    <br>",
"     (B) Tissue vaporization and char tissue formation are visible when high power density is used.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_58_11171=[""].join("\n");
var outline_f10_58_11171=null;
var title_f10_58_11172="Icosapent ethyl (E-EPA): Patient drug information";
var content_f10_58_11172=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Icosapent ethyl (E-EPA): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/26/8612?source=see_link\">",
"     see \"Icosapent ethyl (E-EPA): Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F15162621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Vascepa&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F15157019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691358",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower triglycerides.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F15157018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3973763",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to icosapent ethyl or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F15157023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697830",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use this product if you are allergic to fish.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697317",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have pancreatic disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a blood thinner, have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F15157024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698195",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Joint pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F15157025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699033",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad joint pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F15157021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695929",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695716",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, open, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F15157022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F15157026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F15157027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 86689 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-189.41.172.26-BFFD0AA7E3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_58_11172=[""].join("\n");
var outline_f10_58_11172=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15162621\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15157019\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15157018\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15157023\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15157024\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15157025\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15157021\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15157022\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15157026\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15157027\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/26/8612?source=related_link\">",
"      Icosapent ethyl (E-EPA): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_58_11173="Superior ophthalmic vein";
var content_f10_58_11173=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F69132&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F69132&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    The superior ophthalmic vein is surgically exposed for transvenous embolization of a carotid cavernous fistula",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Vikram D Durairaj, MD, F.A.C.S.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_58_11173=[""].join("\n");
var outline_f10_58_11173=null;
var title_f10_58_11174="Hypertensive complications in blacks";
var content_f10_58_11174=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hypertensive complications in blacks",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/58/11174/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/58/11174/contributors\">",
"     Norman M Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/58/11174/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/58/11174/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/58/11174/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/58/11174/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/58/11174/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension tends to be both more common and more severe in blacks (",
"    <a class=\"graphic graphic_figure graphicRef66935 \" href=\"UTD.htm?7/4/7247\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11174/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition, progression from prehypertension to hypertension is accelerated in blacks [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11174/abstract/2\">",
"     2",
"    </a>",
"    ]. The reasons for these observations are incompletely understood, as the relative importance of environmental and genetic factors have not been established [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11174/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The treatment of hypertension is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/14/15592?source=see_link\">",
"     \"Treatment of hypertension in blacks\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Important risk factors for hypertension among blacks include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lower socioeconomic status",
"     </li>",
"     <li>",
"      Ingestion of a high",
"      <span class=\"nowrap\">",
"       sodium/low",
"      </span>",
"      potassium diet",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another possible mechanism, which is also related to lower socioeconomic class, is poor maternal nutrition leading to low birth weight in the infant. Low birth weight has been associated with an increased risk of hypertension in adulthood, perhaps due in part to impaired renal growth [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11174/abstract/5\">",
"     5",
"    </a>",
"    ]. An associated reduction in renal development with fewer functioning nephrons may contribute to the predisposition to the development of end-stage renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11174/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39477?source=see_link\">",
"     \"Possible role of low birth weight in the pathogenesis of essential hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There may also be a gradient of risk according to geography with standardized prevalences of hypertension of 14 percent in West Africa, 26 percent in the Caribbean, and 33 percent in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11174/abstract/6\">",
"     6",
"    </a>",
"    ]. However, these differences in risk can be explained almost entirely by differences in body mass index since there is a consistent relationship between the prevalence of hypertension and body mass index across black populations [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11174/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RISK OF HYPERTENSIVE COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Black patients with essential hypertension are at much greater risk of developing cardiovascular complications. This is manifested, in comparison to whites, by a three-fold increase in overall cardiovascular mortality, a six- to sevenfold increase in mortality under the age of 50, the earlier development of hypertensive nephrosclerosis, and a 5- to 18-fold rise in the incidence of end-stage renal disease, which is most prominent in the 25 to 45 year age group [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11174/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. (Blacks are also at increased risk for some other renal diseases, particularly diabetic nephropathy) (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/63/30714?source=see_link\">",
"     \"Overview of diabetic nephropathy\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The race-related difference in risk can be largely eliminated by adequate antihypertensive therapy, suggesting an important role for more severe and less well controlled hypertension in blacks [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11174/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Another possible contributing factor is a",
"    <strong>",
"     less prominent decline",
"    </strong>",
"    in nocturnal blood pressure in blacks, thereby increasing the total blood pressure load [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11174/abstract/11\">",
"     11",
"    </a>",
"    ]. One study evaluated 62 black and 72 white treated hypertensives who were matched for the same daytime blood pressure by ambulatory monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11174/abstract/12\">",
"     12",
"    </a>",
"    ]. The mean blood pressure between 1 AM and 5 AM was 7 mmHg higher in the black patients. Why this occurs is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Environmental factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Environmental and socioeconomic factors are also likely to be important. As an example, blacks more frequently ingest a high sodium-low potassium diet [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11174/abstract/13,14\">",
"     13,14",
"    </a>",
"    ], a combination that can both raise the BP and increase the risk of cardiovascular complications. The incidence of salt sensitivity appears to be higher in blacks than in whites due perhaps to upward resetting of the set point for tubuloglomerular feedback [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11174/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/35/24120?source=see_link\">",
"     \"Salt intake, salt restriction, and essential hypertension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13060?source=see_link\">",
"     \"Potassium and hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Indirect evidence in support of the importance of lower socioeconomic status is the observation that Mexican Americans also have an increased (though to a lesser degree) incidence of hypertensive nephrosclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11174/abstract/8\">",
"     8",
"    </a>",
"    ], despite having a slightly lower prevalence of hypertension than non-Hispanic whites [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11174/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Possible genetic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;There may, in addition, be a specific susceptibility to left ventricular hypertrophy and hypertensive nephrosclerosis in blacks. At the same level of blood pressure and total vascular resistance, both left ventricular mass and renal vascular resistance are higher in hypertensive blacks than in hypertensive whites [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11174/abstract/18\">",
"     18",
"    </a>",
"    ]. Furthermore, there appears to be as much as a four to five fold increase in the incidence of hypertensive renal failure in blacks that persists after the severity of hypertension, degree of hypertensive control, and socioeconomic status are taken into account [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11174/abstract/5\">",
"     5",
"    </a>",
"    ]. Even seemingly adequate control of the hypertension may not be completely protective, as the renal disease may continue to progress [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11174/abstract/7,19\">",
"     7,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is also indirect evidence supporting the hypothesis that blacks are particularly susceptible to hypertension-induced renal injury. The overall increase in treating hypertension has led to a reduction in the incidence of stroke and heart failure in both whites and blacks. Despite this clear cardiovascular benefit, there has been a continuing rise in the incidence of end-stage renal disease in older black patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11174/abstract/20\">",
"     20",
"    </a>",
"    ], which is presumably due to hypertensive nephrosclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11174/abstract/7,19\">",
"     7,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It remains uncertain why blacks might be particularly susceptible to renal disease, Genetic factors likely play a role in the increased susceptibility of blacks to hypertensive nephrosclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11174/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Polymorphisms in the genes that encode for podocyte nonmuscle myosin IIa (MYH9) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11174/abstract/21\">",
"     21",
"    </a>",
"    ] and apolipoprotein L1 (APOL1) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11174/abstract/23,24\">",
"     23,24",
"    </a>",
"    ] are found far more commonly in African Americans compared to European Americans. These genetic variations appear to confer a markedly increased risk for nondiabetic ESRD, including that due to hypertensive nephrosclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11174/abstract/22\">",
"     22",
"    </a>",
"    ] and focal segmental glomerulosclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11174/abstract/23\">",
"     23",
"    </a>",
"    ]. The APOL1 variant may have had a survival advantage in Africa due to enhanced defense against sleeping sickness [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11174/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41066?source=see_link&amp;anchor=H9804961#H9804961\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\", section on 'FSGS in African Americans'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another possibility may relate to the autoregulation of renal blood flow. One study evaluated white and black patients with uncomplicated essential hypertension on a low salt diet and then on free salt intake (mean change in sodium excretion from 40 up to 155",
"    <span class=\"nowrap\">",
"     meq/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11174/abstract/25\">",
"     25",
"    </a>",
"    ]. The high salt diet was associated with a rise in glomerular filtration rate of 17",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    in blacks while there was no change in whites. This glomerular hyperfiltration is probably associated with intraglomerular hypertension, a potential risk factor for progressive renal disease. As noted above, this may be particularly likely when maternal malnutrition leads to low birth weight and a reduction in nephron number. Another intrinsic difference in renal function is the increased renal oxygen consumption and oxidative stress observed in blacks compared with whites [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11174/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26938?source=see_link\">",
"     \"Secondary factors and progression of chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     GOAL BLOOD PRESSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In summary, effective antihypertensive therapy is particularly important in black patients. However, the optimal blood pressure in black patients is uncertain. The largest study to address this question was the African American Study of Kidney Disease and Hypertension (AASK) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11174/abstract/27\">",
"     27",
"    </a>",
"    ]. This trial included 1094 African-Americans with long-standing hypertension, otherwise unexplained slowly progressive chronic renal failure, and mild proteinuria (mean about 500 to 600",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    but a median of about 100",
"    <span class=\"nowrap\">",
"     mg/day);",
"    </span>",
"    this pattern in blacks is almost always associated with histologic changes compatible with nephrosclerosis as the sole disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11174/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The patients were allocated to one of three drugs:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/37/24152?source=see_link\">",
"     ramipril",
"    </a>",
"    (463 patients),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    (441 patients), or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    (217 patients), and to one of two blood pressure goals,",
"    <span class=\"nowrap\">",
"     125/75",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     140/90",
"    </span>",
"    mmHg. The primary end point was the rate of change in glomerular filtration rate (GFR); the secondary clinical composite outcome was the time to first event including a 50 percent reduction in GFR, an actual decrease in GFR of 25",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2, the onset of renal failure, or death.",
"   </p>",
"   <p>",
"    At study end after approximately four years, the average blood pressure was",
"    <span class=\"nowrap\">",
"     128/78",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     141/85",
"    </span>",
"    mmHg in the lower and usual blood pressure group, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11174/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. The mean rate of change in GFR and the rate of the secondary composite end point were",
"    <strong>",
"     similar",
"    </strong>",
"    with both blood pressure goals, suggesting that the lower blood pressure goal may not provide further benefit in slowing the progression of renal failure. However, there was a nonsignificant trend favoring the lower blood pressure goal in patients with higher baseline proteinuria. This finding is consistent with the Modification of Diet in Renal Disease trial, in which lower blood pressure goals were most beneficial in those excreting at least 2 to 3 grams of protein per day [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11174/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Consensus recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In November 2010, a consensus statement concerning the management of high blood pressure in African-Americans was published by the International Society on Hypertension in Blacks [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11174/abstract/32\">",
"     32",
"    </a>",
"    ]. For those with",
"    <strong>",
"     uncomplicated",
"    </strong>",
"    essential hypertension, a goal blood pressure less than",
"    <span class=\"nowrap\">",
"     135/85",
"    </span>",
"    mmHg was considered reasonable target.",
"   </p>",
"   <p>",
"    A lower goal of less than",
"    <span class=\"nowrap\">",
"     130/80",
"    </span>",
"    mmHg was recommended in patients at increased risk, such as those with atherosclerotic cardiovascular disease, diabetes, or proteinuric chronic kidney disease. However, the validity of these lower goal blood pressures has been sharply criticized [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11174/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33417?source=see_link\">",
"     \"What is goal blood pressure in the treatment of hypertension?\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29737?source=see_link&amp;anchor=H15#H15\">",
"     \"Blood pressure management in patients with atherosclerotic cardiovascular disease\", section on 'Goal blood pressure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of hypertension in patients with diabetes mellitus\", section on 'Goal blood pressure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link&amp;anchor=H24#H24\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Blood pressure goal'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A discussion of which antihypertensive drugs should be used can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/14/15592?source=see_link\">",
"     \"Treatment of hypertension in blacks\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16514135\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypertension is both more common and more severe in black patients. Risk factors for hypertension among blacks include lower socioeconomic status and ingestion of a high",
"      <span class=\"nowrap\">",
"       sodium/low",
"      </span>",
"      potassium diet. Poor maternal nutrition leading to low birth weight may also contribute. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Black patients with essential hypertension are at greater risk of developing cardiovascular complications. The increased risk of complications is likely due to multiple factors including the increased severity of hypertension, the less prominent decline in nocturnal blood pressure, environmental and socioeconomic factors, and genetic factors. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Risk of hypertensive complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Blacks are particularly susceptible to hypertension-induced renal injury. Genetic polymorphisms and possibly differences in the autoregulation of renal blood flow likely contribute to this increased susceptibility. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Possible genetic factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal goal blood pressure in black patients is uncertain. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Goal blood pressure'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33417?source=see_link\">",
"       \"What is goal blood pressure in the treatment of hypertension?\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29737?source=see_link&amp;anchor=H15#H15\">",
"       \"Blood pressure management in patients with atherosclerotic cardiovascular disease\", section on 'Goal blood pressure'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=see_link&amp;anchor=H10#H10\">",
"       \"Treatment of hypertension in patients with diabetes mellitus\", section on 'Goal blood pressure'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link&amp;anchor=H24#H24\">",
"       \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Blood pressure goal'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11174/abstract/1\">",
"      Carson AP, Howard G, Burke GL, et al. Ethnic differences in hypertension incidence among middle-aged and older adults: the multi-ethnic study of atherosclerosis. Hypertension 2011; 57:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11174/abstract/2\">",
"      Selassie A, Wagner CS, Laken ML, et al. Progression is accelerated from prehypertension to hypertension in blacks. Hypertension 2011; 58:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11174/abstract/3\">",
"      McWilliams JM, Meara E, Zaslavsky AM, Ayanian JZ. Differences in control of cardiovascular disease and diabetes by race, ethnicity, and education: U.S. trends from 1999 to 2006 and effects of medicare coverage. Ann Intern Med 2009; 150:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11174/abstract/4\">",
"      Berenson GS, Chen W, Dasmahapatra P, et al. Stimulus response of blood pressure in black and white young individuals helps explain racial divergence in adult cardiovascular disease: the Bogalusa Heart Study. J Am Soc Hypertens 2011; 5:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11174/abstract/5\">",
"      Lopes AA, Port FK. The low birth weight hypothesis as a plausible explanation for the black/white differences in hypertension, non-insulin-dependent diabetes, and end-stage renal disease. Am J Kidney Dis 1995; 25:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11174/abstract/6\">",
"      Cooper R, Rotimi C. Hypertension in blacks. Am J Hypertens 1997; 10:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11174/abstract/7\">",
"      Bergman S, Key BO, Kirk KA, et al. Kidney disease in the first-degree relatives of African-Americans with hypertensive end-stage renal disease. Am J Kidney Dis 1996; 27:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11174/abstract/8\">",
"      Feldman HI, Klag MJ, Chiapella AP, Whelton PK. End-stage renal disease in US minority groups. Am J Kidney Dis 1992; 19:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11174/abstract/9\">",
"      Ooi WL, Budner NS, Cohen H, et al. Impact of race on treatment response and cardiovascular disease among hypertensives. Hypertension 1989; 14:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11174/abstract/10\">",
"      Otten MW Jr, Teutsch SM, Williamson DF, Marks JS. The effect of known risk factors on the excess mortality of black adults in the United States. JAMA 1990; 263:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11174/abstract/11\">",
"      Prather AA, Blumenthal JA, Hinderliter AL, Sherwood A. Ethnic differences in the effects of the DASH diet on nocturnal blood pressure dipping in individuals with high blood pressure. Am J Hypertens 2011; 24:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11174/abstract/12\">",
"      Hebert LA, Agarwal G, Ladson-Wofford SE, et al. Nocturnal blood pressure in treated hypertensive African Americans Compared to treated hypertensive European Americans. J Am Soc Nephrol 1996; 7:2130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11174/abstract/13\">",
"      Hedayati SS, Minhajuddin AT, Ijaz A, et al. Association of urinary sodium/potassium ratio with blood pressure: sex and racial differences. Clin J Am Soc Nephrol 2012; 7:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11174/abstract/14\">",
"      Frisancho AR, Leonard WR, Bollettino LA. Blood pressure in blacks and whites and its relationship to dietary sodium and potassium intake. J Chronic Dis 1984; 37:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11174/abstract/15\">",
"      Aviv A, Hollenberg NK, Weder AB. Sodium glomerulopathy: tubuloglomerular feedback and renal injury in African Americans. Kidney Int 2004; 65:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11174/abstract/16\">",
"      Aviv A, Hollenberg NK, Weder A. Urinary potassium excretion and sodium sensitivity in blacks. Hypertension 2004; 43:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11174/abstract/17\">",
"      Haffner SM, Mitchell BD, Valdez RA, et al. Eight-year incidence of hypertension in Mexican-Americans and non-Hispanic whites. The San Antonio Heart Study. Am J Hypertens 1992; 5:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11174/abstract/18\">",
"      Kizer JR, Arnett DK, Bella JN, et al. Differences in left ventricular structure between black and white hypertensive adults: the Hypertension Genetic Epidemiology Network study. Hypertension 2004; 43:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11174/abstract/19\">",
"      Rostand SG, Brown G, Kirk KA, et al. Renal insufficiency in treated essential hypertension. N Engl J Med 1989; 320:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11174/abstract/20\">",
"      Li S, McAlpine DD, Liu J, et al. Differences between blacks and whites in the incidence of end-stage renal disease and associated risk factors. Adv Ren Replace Ther 2004; 11:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11174/abstract/21\">",
"      Kopp JB, Smith MW, Nelson GW, et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 2008; 40:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11174/abstract/22\">",
"      Kao WH, Klag MJ, Meoni LA, et al. MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet 2008; 40:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11174/abstract/23\">",
"      Genovese G, Friedman DJ, Ross MD, et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010; 329:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11174/abstract/24\">",
"      Genovese G, Tonna SJ, Knob AU, et al. A risk allele for focal segmental glomerulosclerosis in African Americans is located within a region containing APOL1 and MYH9. Kidney Int 2010; 78:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11174/abstract/25\">",
"      Parmer RJ, Stone RA, Cervenka JH. Renal hemodynamics in essential hypertension. Racial differences in response to changes in dietary sodium. Hypertension 1994; 24:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11174/abstract/26\">",
"      Textor SC, Gloviczki ML, Flessner MF, et al. Association of filtered sodium load with medullary volumes and medullary hypoxia in hypertensive African Americans as compared with whites. Am J Kidney Dis 2012; 59:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11174/abstract/27\">",
"      Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001; 285:2719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11174/abstract/28\">",
"      Fogo A, Breyer JA, Smith MC, et al. Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: a report from the African American Study of Kidney Disease (AASK) Trial. AASK Pilot Study Investigators. Kidney Int 1997; 51:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11174/abstract/29\">",
"      Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288:2421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11174/abstract/30\">",
"      Wright JT Jr, Agodoa L, Contreras G, et al. Successful blood pressure control in the African American Study of Kidney Disease and Hypertension. Arch Intern Med 2002; 162:1636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11174/abstract/31\">",
"      Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994; 330:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11174/abstract/32\">",
"      Flack JM, Sica DA, Bakris G, et al. Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement. Hypertension 2010; 56:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11174/abstract/33\">",
"      Wright JT Jr, Agodoa LY, Appel L, et al. New recommendations for treating hypertension in black patients: evidence and/or consensus? Hypertension 2010; 56:801.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3855 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-84F2B57B49-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_58_11174=[""].join("\n");
var outline_f10_58_11174=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16514135\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RISK OF HYPERTENSIVE COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Environmental factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Possible genetic factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      GOAL BLOOD PRESSURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Consensus recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16514135\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3855\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3855|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/4/7247\" title=\"figure 1\">",
"      Prev htn in men women in US",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29737?source=related_link\">",
"      Blood pressure management in patients with atherosclerotic cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41066?source=related_link\">",
"      Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/63/30714?source=related_link\">",
"      Overview of diabetic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39477?source=related_link\">",
"      Possible role of low birth weight in the pathogenesis of essential hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13060?source=related_link\">",
"      Potassium and hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/35/24120?source=related_link\">",
"      Salt intake, salt restriction, and essential hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26938?source=related_link\">",
"      Secondary factors and progression of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/14/15592?source=related_link\">",
"      Treatment of hypertension in blacks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=related_link\">",
"      Treatment of hypertension in patients with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33417?source=related_link\">",
"      What is goal blood pressure in the treatment of hypertension?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_58_11175="Rho(D) immune globulin (intramuscular): Drug information";
var content_f10_58_11175=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Rho(D) immune globulin (intramuscular): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?8/38/8804?source=see_link\">",
"    see \"Rho(D) immune globulin (intramuscular): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/6/2151?source=see_link\">",
"    see \"Rho(D) immune globulin (intramuscular): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F9838303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F217876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      HyperRHO&trade; S/D Full Dose;",
"     </li>",
"     <li>",
"      HyperRHO&trade; S/D Mini-Dose;",
"     </li>",
"     <li>",
"      MICRhoGAM&reg; UF Plus;",
"     </li>",
"     <li>",
"      RhoGAM&reg; UF Plus;",
"     </li>",
"     <li>",
"      Rhophylac&reg;;",
"     </li>",
"     <li>",
"      WinRho&reg; SDF",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F217877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      WinRho&reg; SDF",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F217891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Blood Product Derivative;",
"     </li>",
"     <li>",
"      Immune Globulin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F217879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      ITP:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rhophylac&reg;: I.V.: 50 mcg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     WinRho&reg; SDF: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Initial: 50 mcg/kg as a single injection, or can be given as a divided dose on separate days. If hemoglobin is &lt;10 g/dL: Dose should be reduced to 25-40 mcg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Subsequent dosing: 25-60 mcg/kg can be used if required to increase platelet count",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maintenance dosing if patient",
"     <b>",
"      did respond",
"     </b>",
"     to initial dosing: 25-60 mcg/kg based on platelet count and hemoglobin concentration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maintenance dosing if patient",
"     <b>",
"      did not respond",
"     </b>",
"     to initial dosing:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Hemoglobin &lt;8 g/dL: Alternative treatment should be used",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Hemoglobin 8-10 g/dL: Redose between 25-40 mcg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Hemoglobin &gt;10 g/dL: Redose between 50-60 mcg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Rh",
"      <sub>",
"       o",
"      </sub>",
"     </b>",
"     <b>",
"      (D) suppression:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     One &ldquo;full dose&rdquo; (300 mcg) provides enough antibody to prevent Rh sensitization if the volume of RBC entering the circulation is &le;15 mL. When &gt;15 mL is suspected, a fetal red cell count should be performed to determine the appropriate dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pregnancy:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Antepartum prophylaxis: In general, dose is given at 28 weeks. If given early in pregnancy, administer every 12 weeks to ensure adequate levels of passively acquired anti-Rh",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     HyperRHO&trade; S/D Full Dose, RhoGAM&reg;: I.M.: 300 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Rhophylac&reg;, WinRho&reg; SDF: I.M., I.V.: 300 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Postpartum prophylaxis: In general, dose is administered as soon as possible after delivery, preferably within 72 hours. Can be given up to 28 days following delivery",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     HyperRHO&trade; S/D Full Dose, RhoGAM&reg;: I.M.: 300 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Rhophylac&reg;: I.M., I.V.: 300 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     WinRho&reg; SDF: I.M., I.V.: 120 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Threatened abortion, any time during pregnancy (with continuation of pregnancy):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     HyperRHO&trade; S/D Full Dose, RhoGAM&reg;: I.M.: 300 mcg; administer as soon as possible",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Rhophylac&reg;, WinRho&reg; SDF: I.M./I.V.: 300 mcg; administer as soon as possible",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Abortion, miscarriage, termination of ectopic pregnancy:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     RhoGAM&reg;: I.M.: &ge;13 weeks gestation: 300 mcg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     HyperRHO&trade; S/D Mini Dose, MICRhoGAM&reg;: &lt;13 weeks gestation: I.M.: 50 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Rhophylac&reg;: I.M., I.V.: 300 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     WinRho&reg; SDF: I.M., I.V.: After 34 weeks gestation: 120 mcg; administer immediately or within 72 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Amniocentesis, chorionic villus sampling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     HyperRHO&trade; S/D Full Dose, RhoGAM&reg;: I.M.: At 15-18 weeks gestation or during the 3rd trimester: 300 mcg. If dose is given between 13-18 weeks, repeat at 26-28 weeks and within 72 hours of delivery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Rhophylac&reg;: I.M., I.V.: 300 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     WinRho&reg; SDF: I.M., I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Before 34 weeks gestation: 300 mcg; administer immediately, repeat dose every 12 weeks during pregnancy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     After 34 weeks gestation: 120 mcg, administered immediately or within 72 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Excessive fetomaternal hemorrhage (&gt;15 mL): Rhophylac&reg;: I.M., I.V.: 300 mcg within 72 hours plus 20 mcg/mL fetal RBCs in excess of 15 mL if excess transplacental bleeding is quantified",
"     <b>",
"      or",
"     </b>",
"     300 mcg/dose if bleeding cannot be quantified",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Abdominal trauma, manipulation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     HyperRHO&trade; S/D Full Dose, RhoGAM&reg;: I.M.: 2nd or 3rd trimester: 300 mcg. If dose is given between 13-18 weeks, repeat at 26-28 weeks and within 72 hours of delivery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Rhophylac&reg;: I.M., I.V.: 300 mcg within 72 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     WinRho&reg; SDF: I.M., I.V.: After 34 weeks gestation: 120 mcg; administer immediately or within 72 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Transfusion:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HyperRHO&trade; S/D Full Dose, RhoGAM&reg;: I.M.: Multiply the volume of Rh positive whole blood administered by the hematocrit of the donor unit to equal the volume of RBCs transfused. The volume of RBCs is then divided by 15 mL, providing the number of 300 mcg doses (vials/syringes) to administer. If the dose calculated results in a fraction, round up to the next higher whole 300 mcg dose (vial/syringe).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     WinRho&reg; SDF: Administer within 72 hours after exposure of incompatible blood transfusions or massive fetal hemorrhage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: Calculate dose as follows; administer 600 mcg every 8 hours until the total dose is administered:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Exposure to Rh",
"     <sub>",
"      o",
"     </sub>",
"     (D) positive whole blood: 9 mcg/mL blood",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Exposure to Rh",
"     <sub>",
"      o",
"     </sub>",
"     (D) positive red blood cells: 18 mcg/mL cells",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M.: Calculate dose as follows; administer 1200 mcg every 12 hours until the total dose is administered:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Exposure to Rh",
"     <sub>",
"      o",
"     </sub>",
"     (D) positive whole blood: 12 mcg/mL blood",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Exposure to Rh",
"     <sub>",
"      o",
"     </sub>",
"     (D) positive red blood cells: 24 mcg/mL cells",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rhophylac&reg;: I.M., I.V.:20 mcg per 2 mL transfused blood or 1 mL erythrocyte concentrate",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F217888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/6/2151?source=see_link\">",
"      see \"Rho(D) immune globulin (intramuscular): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      ITP, transfusion:",
"     </b>",
"     Rhophylac&reg;, WinRho&reg; SDF: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Patients &gt;65 years of age with a concurrent comorbid condition (eg, infection, malignancy, autoimmune disorders) may be at increased risk of developing acute hemolytic reactions. Fatal outcomes associated with IVH have occurred most frequently in those &gt;65 years. Careful consideration should be used when selecting dosage for elderly patients due to a higher probability of decreased hepatic, renal, or cardiac function; consider starting at lower doses.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F2522345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V. infusion: Use caution; may require infusion rate reduction or discontinuation.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F217855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HyperRHO&trade; S/D Full Dose: 300 mcg/mL (1 mL) [&ge;1500 units; for I.M. use only]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HyperRHO&trade; S/D Mini-Dose: 50 mcg/0.17 mL (0.17 mL) [&ge;250 units; for I.M. use only]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     MICRhoGAM&reg; UF Plus: 50 mcg/0.75 mL (0.75 mL) [contains polysorbate 80; 250 units; for I.M. use only; volume is expressed as an approximate value]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     RhoGAM&reg; UF Plus: 300 mcg/0.75 mL (0.75 mL) [contains polysorbate 80; 1500 units; for I.M. use only; volume is expressed as an approximate value]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rhophylac&reg;: 300 mcg/2 mL (2 mL) [contains albumin (human); 1500 units; for I.M. or I.V. use]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     WinRho&reg; SDF: 3000 mcg/~13 mL (13 mL) [contains maltose, polysorbate 80; 15,000 units; for I.M. or I.V. use; volume is expressed as an approximate value]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     WinRho&reg; SDF: 300 mcg/~1.3 mL (1.3 mL) [contains maltose, polysorbate 80; 1500 units; for I.M. or I.V. use; volume is expressed as an approximate value]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     WinRho&reg; SDF: 500 mcg/~2.2 mL (2.2 mL) [contains maltose, polysorbate 80; 2500 units; for I.M. or I.V. use; volume is expressed as an approximate value]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     WinRho&reg; SDF: 1000 mcg/~4.4 mL (4.4 mL) [contains maltose, polysorbate 80; 5000 units; for I.M. or I.V. use; volume is expressed as an approximate value]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F217839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F217857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The total volume can be administered in divided doses at different sites at one time or may be divided and given at intervals, provided the total dosage is given within 72 hours of the fetomaternal hemorrhage or transfusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M.: Administer into the deltoid muscle of the upper arm or anterolateral aspect of the upper thigh; avoid gluteal region due to risk of sciatic nerve injury. If large doses (&gt;5 mL) are needed, administration in divided doses at different sites is recommended.",
"     <b>",
"      Note:",
"     </b>",
"     Do not administer I.M. Rh",
"     <sub>",
"      o",
"     </sub>",
"     (D) immune globulin for ITP.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rhophylac&reg;: ITP: Infuse at 2 mL per 15-60 seconds",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     WinRho&reg; SDF: Infuse over at least 3-5 minutes; do not administer with other medications",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     If preparing dose using liquid formulation, withdraw the entire contents of the vial to ensure accurate calculation of the dosage requirement.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F217856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suppression of Rh isoimmunization: Use in the following situations when an Rh",
"     <sub>",
"      o",
"     </sub>",
"     (D)-negative individual is exposed to Rh",
"     <sub>",
"      o",
"     </sub>",
"     (D)-positive blood: During delivery of an Rh",
"     <sub>",
"      o",
"     </sub>",
"     (D)-positive infant; abortion; amniocentesis; chorionic villus sampling; ruptured tubal pregnancy; abdominal trauma; hydatidiform mole; transplacental hemorrhage. Used when the mother is Rh",
"     <sub>",
"      o",
"     </sub>",
"     (D)-negative, the father of the child is either Rh",
"     <sub>",
"      o",
"     </sub>",
"     (D)-positive or Rh",
"     <sub>",
"      o",
"     </sub>",
"     (D)-unknown, or the baby is either Rh",
"     <sub>",
"      o",
"     </sub>",
"     (D)-positive or Rh",
"     <sub>",
"      o",
"     </sub>",
"     (D)-unknown.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Transfusion: Suppression of Rh isoimmunization in Rh",
"     <sub>",
"      o",
"     </sub>",
"     (D)-negative individuals transfused with Rh",
"     <sub>",
"      o",
"     </sub>",
"     (D) antigen-positive RBCs or blood components containing Rh",
"     <sub>",
"      o",
"     </sub>",
"     (D) antigen-positive RBCs",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Treatment of idiopathic thrombocytopenic purpura (ITP): Used intravenously in the following nonsplenectomized Rh",
"     <sub>",
"      o",
"     </sub>",
"     (D)-positive individuals: Children with acute or chronic ITP, adults with chronic ITP, and children and adults with ITP secondary to HIV infection",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F217889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hyper-/hypotension, pallor, vasodilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills, dizziness, fever, headache, malaise, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Haptoglobin decreased, hemoglobin decreased (patients with ITP), intravascular hemolysis (patients with ITP)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Bilirubin increased, LDH increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site reaction: Discomfort, induration, mild pain, redness, swelling",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back pain, hyperkinesia, myalgia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Acute renal insufficiency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, diaphoresis, infusion-related reactions, positive anti-C antibody test (transient), shivering",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Anemia (clinically-compromising), anuria, ARDS, cardiac arrest, cardiac failure, chest pain, chromaturia, DIC, edema, erythema, fatigue, hematuria, hemoglobinemia, hemoglobinuria (transient in patients with ITP), hyperhidrosis, hypersensitivity, injection site irritation, jaundice, myocardial infarction, muscle spasm, nausea, pain in extremities, renal failure, renal impairment, tachycardia, transfusion-related acute lung injury",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F217860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to immune globulins or any component of the formulation; prior sensitization to Rh",
"     <sub>",
"      o",
"     </sub>",
"     (D)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     WinRho&reg; SDF product labeling: Patients with autoimmune hemolytic anemia; patients with pre-existing hemolysis or at high risk for hemolysis; IgA-deficient patients with antibodies against IgA; suppression of isoimmunization in infants",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     WinRho&reg; SDF Canadian labeling: Additional contraindications (not in U.S. labeling):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Rh immunization prophylaxis: Rh",
"     <sub>",
"      o",
"     </sub>",
"     (D)-negative women who are not pregnant or have had a recent delivery or abortion and who are Rh sensitized",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Treatment of ITP: Patients who are Rh",
"     <sub>",
"      o",
"     </sub>",
"     (D)-negative or have had splenectomy, ITP secondary to conditions including leukemia, lymphoma, or active infections with Epstein-Barr virus (EBV) or hepatits C virus (HCV), elderly with comorbidities predisposing to acute hemolytic reaction (AHR), evidence of autoimmune hemolytic anemia (Evan&rsquo;s syndrome), systemic lupus erythematosus (SLE) or antiphospholipid antibody syndrome",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F217843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylaxis: Use with caution in patients with IgA deficiency, may contain trace amounts of IgA; patients who are IgA deficient may have the potential for developing IgA antibodies, anaphylactic reactions may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Intravascular hemolysis:",
"     <b>",
"      [U.S. Boxed Warning]: May cause fatal intravascular hemolysis (IVH) in patients treated for immune thrombocytopenic purpura",
"     </b>",
"     (WinRho&reg; SDF product labeling). Rare but serious signs and symptoms (eg, back pain, shaking, chills, fever, discolored urine; onset within 4 hours of infusion) of IVH have been reported in postmarketing experience in patients treated for ITP and may result in clinically-compromising anemia and multiorgan system failure including acute respiratory distress syndrome. Acute renal insufficiency and disseminated intravascular coagulation (DIC) have also been reported. ITP patients should be advised of the signs and symptoms of IVH and instructed to report them immediately.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thrombotic events: Thrombotic events have been reported with administration of intravenous immune globulins (IVIG); use with caution in patients with a history of atherosclerosis or cardiovascular and/or thrombotic risk factors or patients with known/suspected hyperviscosity. Consider a baseline assessment of blood viscosity in patients at risk for hyperviscosity. Administer at the minimum practical infusion rate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Transfusion-related acute lung injury: Pulmonary edema may occur following IVIG treatment in patients being treated for ITP. Symptoms are usually present within 1-6 hours after administration; monitor patients for pulmonary reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding disorders: Use with caution in patients with thrombocytopenia or coagulation disorders; bleeding/hematoma may occur from I.M. administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immune globulin deficiency syndromes: Not for replacement therapy in immune globulin deficiency syndromes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; ITP: Appropriate use: Safety and efficacy not established in Rh",
"     <sub>",
"      o",
"     </sub>",
"     (D) negative, non-ITP thrombocytopenia, or splenectomized patients. Decrease dose with hemoglobin &lt;10 g/dL; use with extreme caution if hemoglobin &lt;8 g/dL. Do not administer I.M. or SubQ; administer dose I.V. only.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; administer at the minimum practical infusion rate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Rh",
"     <sub>",
"      o",
"     </sub>",
"     (D) suppression: For use in the mother; do not administer to the neonate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Human plasma: Product of human plasma; may potentially contain infectious agents which could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Maltose: Some products may contain maltose, which may result in falsely-elevated blood glucose readings.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Rhophylac&reg;: Safety and efficacy have not been established for Rhophylac&reg; in patients with anemia.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F217848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immune Globulins may diminish the therapeutic effect of Vaccines (Live).  Management: Live organism vaccination should be withheld for up to 6 months following immune globulin administration.  Live vaccine given immediately prior to immune globulin may require repeat vaccination.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Yellow Fever Vaccine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F217851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F217863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have not been conducted. Available evidence suggests that Rh",
"     <sub>",
"      o",
"     </sub>",
"     (D) immune globulin administration during pregnancy does not harm the fetus or affect future pregnancies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F217883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Does not enter breast milk",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F3422280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Injection",
"     </b>",
"     (HyperRHO S/D Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mcg (1): $39.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mcg (1): $110.27",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Injection",
"     </b>",
"     (MICRhoGAM Ultra-Filtered Plus Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mcg (1): $60.34",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Injection",
"     </b>",
"     (RhoGAM Ultra-Filtered Plus Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mcg (1): $141.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Rhophylac Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1500 units/2 mL (2 mL): $192.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (WinRho SDF Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1500 unit/1.3 mL (1.3 mL): $403.01",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2500 unit/2.2 mL (2.2 mL): $675.85",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5000 unit/4.4 mL (4.4 mL): $1351.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15000 unit/13 mL (13 mL): $4055.14",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F217853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Signs and symptoms of intravascular hemolysis (IVH), anemia, renal insufficiency, back pain, shaking, chills, discolored urine, or hematuria; observe patient for side effects for 8 hours following administration",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Patients with suspected IVH: CBC, haptoglobin, plasma hemoglobin, urine dipstick, BUN, serum creatinine, liver function tests, DIC-specific tests (D-dimer, fibrin degradation products [FDP] or fibrin split products [FSP]) for differential diagnosis. In patients at increased risk of developing acute renal failure, periodically monitor renal function and urine output. Clinical response may be determined by monitoring platelets, red blood cell (RBC) counts, hemoglobin, and reticulocyte levels.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     ITP: Check blood type, CBC, reticulocyte count, DAT, urine dipstick before initiating treatment with WinRho&reg; SDF, repeat urine dipstick at 2 and 4 hours after administration and prior to end of the 8-hour monitoring period.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F217864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Bay Rho-D (IL);",
"     </li>",
"     <li>",
"      BayRHo-D (ID);",
"     </li>",
"     <li>",
"      Hyperrho-D (TW);",
"     </li>",
"     <li>",
"      IGRHO (IL);",
"     </li>",
"     <li>",
"      KamRho-D IM (IL);",
"     </li>",
"     <li>",
"      KamRho-D IV (IL);",
"     </li>",
"     <li>",
"      Natead (FR);",
"     </li>",
"     <li>",
"      Partobulin (CZ, GB, HK, IT, TR);",
"     </li>",
"     <li>",
"      Partogamma (IT);",
"     </li>",
"     <li>",
"      Partogloman (AT);",
"     </li>",
"     <li>",
"      Probi RHO (D) (MX);",
"     </li>",
"     <li>",
"      Rhesogam (DE);",
"     </li>",
"     <li>",
"      Rhesogamma (SE);",
"     </li>",
"     <li>",
"      Rhesogamma P (AR);",
"     </li>",
"     <li>",
"      Rhesonativ (AE, BH, CY, DE, DK, EE, EG, IL, IQ, IR, JO, KW, LB, LY, NO, OM, QA, SA, SE, SY, YE);",
"     </li>",
"     <li>",
"      Rhesugam (ZA);",
"     </li>",
"     <li>",
"      Rhesuman (CH, ES, GR, IN, IT, PK, TR);",
"     </li>",
"     <li>",
"      Rhesuman Berna (CO, HK, IL, MY, TH);",
"     </li>",
"     <li>",
"      Rhogam (BE, HK);",
"     </li>",
"     <li>",
"      Rhophylac (FR, GB, IL);",
"     </li>",
"     <li>",
"      WinRho SDF (AU, IL, PH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F217842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rh suppression: Prevents isoimmunization by suppressing the immune response and antibody formation by Rh",
"     <sub>",
"      o",
"     </sub>",
"     (D) negative individuals to Rh",
"     <sub>",
"      o",
"     </sub>",
"     (D) positive red blood cells.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     ITP: Not completely characterized; Rh",
"     <sub>",
"      o",
"     </sub>",
"     (D) immune globulin is thought to form anti-D-coated red blood cell complexes which bind to macrophage Fc receptors within the spleen;  blocking or saturating the spleens ability to clear antibody-coated cells, including platelets. In this manner, platelets are spared from destruction.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F217859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of platelet increase: ITP: Platelets should rise within 1-2 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: In 7-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Suppression of Rh isoimmunization: ~12 weeks; Treatment of ITP: 30 days (variable)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : I.M.: 8.59 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: I.M.: Rhophylac&reg;: 69%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~24-30 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: I.M.: 5-10 days; I.V. (WinRho&reg; SDF): &le;2 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Gaines AR, \"Acute Onset Hemoglobinemia and/or Hemoglobinuria and Sequelae Following Rho(D) Immune Globulin Intravenous Administration in Immune Thrombocytopenic Purpura Patients,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2000, 95(8):2523-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/58/11175/abstract-text/10753830/pubmed\" id=\"10753830\" target=\"_blank\">",
"        10753830",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gaines AR, \"Disseminated Intravascular Coagulation Associated with Acute Hemoglobinemia or Hemoglobinuria Following Rho(D) Immune Globulin Intravenous Administration for Immune Thrombocytopenic Purpura,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2005, 106(5):1532-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/58/11175/abstract-text/15878975/pubmed\" id=\"15878975\" target=\"_blank\">",
"        15878975",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      George JN, Woolf SH, Raskob GE, et al, \"Clinical Guideline: Diagnosis and Treatment of Idiopathic Thrombocytopenic Purpura: Recommendations of the American Society of  Hematology,\"",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1997, 126(4):319-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/58/11175/abstract-text/9036806/pubmed\" id=\"9036806\" target=\"_blank\">",
"        9036806",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hartwell EA, &ldquo;Use of Rh Immune Globulin: ASCP Practice Parameter. American Society of Clinical Pathologists,&rdquo;",
"      <i>",
"       Am J Clin Pathol",
"      </i>",
"      , 1998, 110(3):281-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/58/11175/abstract-text/9728602/pubmed\" id=\"9728602\" target=\"_blank\">",
"        9728602",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Rh",
"      <sub>",
"       o",
"      </sub>",
"      (D) Immune Globulin I.V. for Prevention of Rh Isoimmunization and for Treatment of ITP,&rdquo;",
"      <i>",
"       Med Lett Drugs Ther",
"      </i>",
"      , 1996, 38(966):6-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/58/11175/abstract-text/8544794/pubmed\" id=\"8544794\" target=\"_blank\">",
"        8544794",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Simpson KN, Coughlin CM, Eron J, et al, &ldquo;Idiopathic Thrombocytopenia Purpura: Treatment Patterns and an Analysis of Cost Associated With Intravenous Immunoglobulin and Anti-D Therapy,&rdquo;",
"      <i>",
"       Semin Hematol",
"      </i>",
"      , 1998, 35(1 Suppl 1):58-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/58/11175/abstract-text/9523750/pubmed\" id=\"9523750\" target=\"_blank\">",
"        9523750",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scaradavou A, Bussel J. &ldquo;Clinical Experience With Anti-D in the Treatment of Idiopathic Thrombocytopenic Purpura.&rdquo;",
"      <i>",
"       Semin Hematol",
"      </i>",
"      , 1998, 35(1 Suppl 1):52-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/58/11175/abstract-text/9523749/pubmed\" id=\"9523749\" target=\"_blank\">",
"        9523749",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ware RE and Zimmerman SA, &ldquo;Anti-D: Mechanisms of Action,&rdquo;",
"      <i>",
"       Semin Hematol",
"      </i>",
"      , 1998, 35(1 Suppl 1):14-22.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9858 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-218.7.204.208-7855FF150B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_58_11175=[""].join("\n");
var outline_f10_58_11175=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9838303\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217876\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217877\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217891\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217879\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217888\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062198\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2522345\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217855\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217839\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217857\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217856\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217889\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217860\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217843\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299995\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217848\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217851\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217863\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217883\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3422280\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217853\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217864\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217842\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217859\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9858\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9858|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?8/38/8804?source=related_link\">",
"      Rho(D) immune globulin (intramuscular): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/6/2151?source=related_link\">",
"      Rho(D) immune globulin (intramuscular): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_58_11176="Midgut formation";
var content_f10_58_11176=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63200&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63200&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 602px\">",
"   <div class=\"ttl\">",
"    Midgut formation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 582px; height: 590px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left side views (A and B) of the counterclockwise 180&deg; rotation of the midgut loop as it is withdrawn into the abdominal cavity. C) The descent of the cecum takes place later.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Snell, MD, PhD, Clinical Anatomy, 7th ed. Lippincott Williams &amp; Wilkins, 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_58_11176=[""].join("\n");
var outline_f10_58_11176=null;
var title_f10_58_11177="Recurrent pericarditis";
var content_f10_58_11177=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Recurrent pericarditis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/58/11177/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/58/11177/contributors\">",
"     Yehuda Adler, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/58/11177/contributors\">",
"     Massimo Imazio, MD, FESC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/58/11177/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/58/11177/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/58/11177/contributors\">",
"     Jae K Oh, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/58/11177/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/58/11177/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/58/11177/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent pericarditis is a common and often vexing problem for specialists in pericardial disease as well as general internists and family clinicians [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/1\">",
"     1",
"    </a>",
"    ]. The term refers to a syndrome in which acute pericarditis recurs after the agent inciting the original acute attack has disappeared or has ceased to be active [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. The exact recurrence rate after initial attacks of idiopathic pericarditis is unknown, but may be as high as 15 to 30 percent in patients not treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/3,6-8\">",
"     3,6-8",
"    </a>",
"    ]. Some patients, however, have more persistent pericarditis in which symptoms can only be controlled with steroidal therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/7,9\">",
"     7,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Issues related to recurrent pericarditis are reviewed here. The evaluation and management of patients with acute pericarditis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37625?source=see_link\">",
"     \"Clinical presentation and diagnostic evaluation of acute pericarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent pericarditis is manifested by recurrence of the symptoms of acute pericarditis (",
"    <a class=\"graphic graphic_table graphicRef64302 \" href=\"UTD.htm?24/22/24939\">",
"     table 1",
"    </a>",
"    ). The major clinical manifestations of acute pericarditis are chest pain, pericardial friction rub, widespread saddle-shaped or concave upward ST segment elevation on the electrocardiogram (ECG), and pericardial effusion [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/6\">",
"     6",
"    </a>",
"    ]. At least two of these features should usually be present to make the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37625?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical presentation and diagnostic evaluation of acute pericarditis\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     COlchicine",
"    </a>",
"    for REcurrent pericarditis (CORE) trial, the following definition was used for recurrent pericarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A documented first attack of acute pericarditis.",
"     </li>",
"     <li>",
"      Evidence of either recurrence or continued activity of pericarditis. Criteria for the diagnosis of recurrence included recurrent pain and one or more of the following signs: fever, pericardial friction rub, electrocardiographic changes, echocardiographic evidence of pericardial effusion, cardiac magnetic resonance imaging (MRI) evidence of inflammation of the pericardium, and an elevation in the white blood cell count, erythrocyte sedimentation rate, or C-reactive protein.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of recurrent pericarditis are considered to be autoimmune. Evidence supporting an immunopathologic process includes a latent period lasting for months and similarities to other autoimmune conditions including the presence of autoantibodies and responsiveness to glucocorticoid and other immunosuppressive therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. An infectious or systemic etiology cannot usually be identified using standard laboratory techniques without supplementary molecular biology techniques.",
"   </p>",
"   <p>",
"    Recurrent pericarditis shares many features of the postcardiac injury syndrome, which may also be associated with recurrences [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/31/24055?source=see_link&amp;anchor=H12#H12\">",
"     \"Pericardial complications of myocardial infarction\", section on 'Postcardiac injury syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    European investigators working in a specialized laboratory performed extensive studies to evaluate suspected recurrent pericarditis including pericardioscopy, multiple epicardial biopsies, and polymerase chain reaction (PCR) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/13\">",
"     13",
"    </a>",
"    ]. Epicardial biopsy was performed during pericardioscopy and targeted at regions that appeared abnormal. Biopsy of the subendocardium or the parietal pericardium may not be sufficient since inflammation may be limited to the epicardium (including the visceral pericardium). This intensive approach is not widely used in the United States and Europe.",
"   </p>",
"   <p>",
"    The authors reported a higher prevalence of infection or reinfection (about 23 percent) than reported in other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/7,13\">",
"     7,13",
"    </a>",
"    ]. In many cases, infection may be missed on routine evaluation and only detected by PCR. These observations suggest that the proportion of cases caused by an autoimmune response may be frequently overestimated.",
"   </p>",
"   <p>",
"    Based on these findings, the task force on pericardial diseases of the European Society of Cardiology established the following criteria for the diagnosis of \"autoreactive\" pericarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pericardial fluid revealing",
"      <span class=\"nowrap\">",
"       &gt;5000/mm3",
"      </span>",
"      mononuclear cells (lymphocytes and monocytes) or antisarcolemmal antibodies",
"     </li>",
"     <li>",
"      Inflammation in",
"      <span class=\"nowrap\">",
"       epicardial/endomyocardial",
"      </span>",
"      biopsies by &ge;14",
"      <span class=\"nowrap\">",
"       cells/mm2",
"      </span>",
"     </li>",
"     <li>",
"      Exclusion of active viral infection both in pericardial effusion and",
"      <span class=\"nowrap\">",
"       endocardial/epicardial",
"      </span>",
"      biopsies",
"     </li>",
"     <li>",
"      Tuberculosis, Borrelia burgdorferi, Chlamydia pneumoniae, and other bacterial infection excluded by PCR",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cultures",
"     </li>",
"     <li>",
"      Neoplastic infiltration absent in pericardial effusion and biopsy samples",
"     </li>",
"     <li>",
"      Exclusion of systemic, metabolic disorders, and uremia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with autoreactive pericarditis, cytokines such as interleukin (IL)-6, IL-8, and interferon gamma have been detected in the pericardial fluid but not in sera [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/14\">",
"     14",
"    </a>",
"    ]. This distribution of cytokines suggests a local inflammatory process.",
"   </p>",
"   <p>",
"    Familial factors may be important in some cases. A cluster of recurrent pericarditis has been described in five members of a family of German and Danish ancestry [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/15\">",
"     15",
"    </a>",
"    ]. It was suggested that this might represent familial disease with possible autosomal dominant inheritance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL COURSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first symptoms of recurrent pericarditis occur at a variable time after the initial attack, but usually within 18 months [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/8,16\">",
"     8,16",
"    </a>",
"    ]. Most patients with recurrent pericarditis are well between attacks, although some patients have a more persistent or chronic course [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/7,9\">",
"     7,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The index attack is usually more severe than recurrent episodes. In the intermittent form, symptoms are found after a symptom-free interval longer than six weeks after drug withdrawal (six weeks being an arbitrarily defined interval) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/17\">",
"     17",
"    </a>",
"    ]. In incessant forms, recurrent symptoms appear within six weeks after drug discontinuation or during attempted weaning. This may be observed following NSAID use, but more commonly following glucocorticoid therapy.",
"   </p>",
"   <p>",
"    The number of recurrences and the intervals between them vary considerably among patients: 40 to 50 percent have only one to two recurrences [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/10,16,17\">",
"     10,16,17",
"    </a>",
"    ], usually occurring over several months to a few years or, in some cases, as long as 15 years [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/3\">",
"     3",
"    </a>",
"    ] or 43 years [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/12\">",
"     12",
"    </a>",
"    ]. As an example, in a study following 31 patients with recurrent pericarditis for 2 to 19 years, the duration of the recurrent process was five years or more in 19 of the patients, and eight years or more in seven [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most frequent symptom of recurrent pericarditis is chest pain, which may follow exertion. Some patients report dyspnea but tamponade, which can cause dyspnea, is a rare complication, even in patients who had tamponade during the initial episode [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Overall prognosis is excellent for most patients with idiopathic recurrent pericarditis. Severe complications are uncommon even with multiple recurrences [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/2-4,10,12,16-18\">",
"     2-4,10,12,16-18",
"    </a>",
"    ]. The prevalence of pericardial effusion and cardiac tamponade decrease with subsequent episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/12,17,19\">",
"     12,17,19",
"    </a>",
"    ]. Recurrent pericarditis is not associated with myocardial systolic dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/12,17\">",
"     12,17",
"    </a>",
"    ]. Although constrictive pericarditis has been reported in one family cluster with recurrent pericarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/15\">",
"     15",
"    </a>",
"    ], idiopathic recurrent pericarditis is not associated with constriction [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/12,17,20\">",
"     12,17,20",
"    </a>",
"    ]. However, quality of life can be severely affected in patients with repeated recurrences or incessant pericarditis and glucocorticoid dependence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Predictors of recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;No presenting clinical feature of an initial episode of acute pericarditis reliably predicts recurrence but the response to therapy and type of therapy for the initial episode may have some prognostic value.",
"   </p>",
"   <p>",
"    The response of patients with presumed idiopathic acute pericarditis to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or other nonsteroidal antiinflammatory drug (NSAID) may identify those at particular risk of recurrence. This was suggested in a review of 254 low-risk patients (patients with none of the following high-risk features: fever &gt;38 degrees C, subacute onset, compromised immune status, trauma, oral anticoagulant therapy, myopericarditis, large or massive pericardial effusion, or cardiac tamponade) with acute pericarditis, 33 of whom (13 percent) did not respond to outpatient aspirin therapy, which was defined as persistence of fever, a new pericardial effusion, or worsening of general illness after seven days [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/6\">",
"     6",
"    </a>",
"    ]. These patients, compared to those who responded to aspirin, had a much higher rate of recurrent pericarditis (61 versus 10 percent) and of pericardial constriction (9.1 versus 0.5 percent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37625?source=see_link\">",
"     \"Clinical presentation and diagnostic evaluation of acute pericarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Initial concerns that glucocorticoid therapy for acute pericarditis may promote recurrence have been confirmed in subsequent studies. The best data come from the COPE trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    therapy in patients with a first episode of acute pericarditis in which glucocorticoids were given only when",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    was contraindicated or not tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/8\">",
"     8",
"    </a>",
"    ]. On multivariate analysis, glucocorticoid use was a significant predictor of recurrence (odds ratio 4.30), an effect that may be due to promotion of viral replication [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/21\">",
"     21",
"    </a>",
"    ]. The COPE trial also showed that colchicine therapy markedly reduces the rate of recurrence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/44/713?source=see_link&amp;anchor=H12602686#H12602686\">",
"     \"Treatment of acute pericarditis\", section on 'Colchicine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similar findings were noted in the CORE trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    therapy in patients with recurrent pericarditis by the same investigators [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/10\">",
"     10",
"    </a>",
"    ]. Previous glucocorticoid use was an independent risk factor for further recurrences (odds ratio 2.89). Similar findings have been noted in other reports [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/16,22\">",
"     16,22",
"    </a>",
"    ]. In addition, glucocorticoid therapy may reduce the efficacy of colchicine in preventing recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Colchicine'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent pericarditis can be a prolonged and frustrating disease with disabling pain and malaise. Because of this and the need to maintain compliance, effective communication with the patient is important.",
"   </p>",
"   <p>",
"    The treatment of recurrent pericarditis is similar to that of the initial acute episode. Outpatient management is feasible in almost all cases [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/10,16\">",
"     10,16",
"    </a>",
"    ]. Hospitalization should be limited to patients with high-risk features as in acute pericarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37625?source=see_link&amp;anchor=H19#H19\">",
"     \"Clinical presentation and diagnostic evaluation of acute pericarditis\", section on 'Determination of risk and need for hospitalization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many patients report worsening symptoms following physical exertion. Although supporting evidence is not available, it may be reasonable to restrict exertion in such patients to that necessary to perform domestic tasks and undertake sedentary work [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We recommend",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or another nonsteroidal antiinflammatory drug plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    for initial therapy of recurrent pericarditis due to idiopathic or viral causes. In patients with another identified cause, specific therapy appropriate to the underlying disorder is indicated (see appropriate topic reviews). (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Nonsteroidal antiinflammatory drugs'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The vast majority of patients will also respond to glucocorticoids (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ), initially given in a high dose, which is maintained for a short period and subsequently tapered. However, prolonged or frequent administration may be necessary, possibly leading to serious complications. In addition, glucocorticoid therapy may increase the rate of recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/8,10,21-24\">",
"     8,10,21-24",
"    </a>",
"    ] even after multiple recurrences [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/22\">",
"     22",
"    </a>",
"    ]. As a result, it is recommended that the use of glucocorticoids for recurrent pericarditis be",
"    <strong>",
"     limited",
"    </strong>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Communication with the patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to explain to the patient the nature of the disease, the likely course, and the treatment alternatives. Specific features of the disease that should be emphasized include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After successful treatment of a recurrence, further recurrences are possible, and may repeat, at variable intervals, for up to several years.",
"     </li>",
"     <li>",
"      Recurrent episodes are not usually caused by reinfection, even among patients whose first illness was viral. It is reasonable to reassure such patients that the disease eventually disappears in most cases, almost always with no permanent sequelae.",
"     </li>",
"     <li>",
"      Symptoms of cardiac tamponade, which is a rare complication of recurrent pericarditis. Constrictive pericarditis almost never occurs. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=see_link\">",
"       \"Cardiac tamponade\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/12/12490?source=see_link\">",
"       \"Constrictive pericarditis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Indications for pericardiectomy as well as the reasons for delaying a decision to proceed with the operation. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Role of pericardiectomy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Complications of immunosuppression. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"       \"Major side effects of systemic glucocorticoids\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Nonsteroidal antiinflammatory drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with acute pericarditis, NSAIDS are part of the first-line therapy of recurrent pericarditis. The 2004 European Society of Cardiology (ESC) guidelines recommended NSAIDs for the treatment of acute pericarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/11\">",
"     11",
"    </a>",
"    ]. The different NSAIDs are probably equally effective but must be given in appropriate antiinflammatory doses. Gastrointestinal protection should be provided during NSAID therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The patient's prior experience can provide a useful guide for deciding among agents. Many patients with recurrent pericarditis have tried a number of different NSAIDs at different times. If a patient reports that a specific drug has proven effective, it is reasonable to use that agent. This approach should be maintained until it is clear that NSAIDs have failed to control the syndrome, especially the pain, or that the drugs are not tolerated.",
"   </p>",
"   <p>",
"    In the absence of evidence of patient preference, our first choice is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (750 to 1000 mg three times daily), while",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    (600 mg three times daily) is an acceptable alternative.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     Indomethacin",
"    </a>",
"    (50 mg three times daily) is usually reserved for more severe cases and when first-line NSAIDs fail (",
"    <a class=\"graphic graphic_table graphicRef50462 \" href=\"UTD.htm?24/48/25355\">",
"     table 2",
"    </a>",
"    ). If the initial response to therapy is not satisfactory, the dose of the NSAID should be increased (up to the recommended daily maximum dose), or an alternative antiinflammatory agent used, until an adequate response is achieved.",
"   </p>",
"   <p>",
"    The NSAID dose should be given in three doses daily to achieve better control of symptoms for one to two weeks until symptom resolution. Following symptom resolution, NSAIDs should be tapered to reduce the subsequent recurrence rate [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/6,8,10,16,25,26\">",
"     6,8,10,16,25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    (2000 to 4000",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in divided doses) may be preferable in post-myocardial infarction patients or those taking aspirin as an antiplatelet agent, since",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    and some other NSAIDs can interfere with the antiplatelet effect of low-dose aspirin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24648?source=see_link\">",
"     \"Nonselective NSAIDs: Adverse cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Colchicine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     Colchicine",
"    </a>",
"    is commonly given in combination with NSAIDS for the treatment of recurrent pericarditis. The use of colchicine with or without NSAIDs can reduce or eliminate the need for glucocorticoids in patients with recurrent pericarditis. We recommend that patients with recurrent pericarditis be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or other NSAID plus colchicine using a regimen similar to the CORE and CORP trials (up to 2 mg on the first day, followed by 0.6 mg once or twice daily for six months) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/10,27\">",
"     10,27",
"    </a>",
"    ]. Colchicine should be prescribed in two doses daily rather than a single dose to reduce the risk of gastrointestinal intolerance and improve patient compliance [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effectiveness of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    in patients with recurrent pericarditis has been evaluated in two randomized, placebo controlled trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the CORE trial, 84 consecutive patients with a first episode of recurrent pericarditis were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      alone or in combination with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      (1 to 2 mg on the first day, followed by 0.5 once or twice daily for six months) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/10\">",
"       10",
"      </a>",
"      ]. Colchicine therapy was associated with a marked and significant reduction in the primary endpoint of the rate of recurrence at 18 months (24 versus 51 percent), and a significant reduction in the secondary endpoint symptom persistence at 72 hours (10 versus 31 percent).",
"     </li>",
"     <li>",
"      In the CORP trial, 120 consecutive patients with a first episode of recurrent pericarditis were randomly assigned to conventional therapy alone (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ) or in combination with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      (1 to 2 mg on the first day, followed by 0.5 once or twice daily for six months) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/27\">",
"       27",
"      </a>",
"      ]. Treatment with colchicine significantly reduced the primary endpoint of first recurrence at 18 months (24 versus 55 percent with placebo, absolute risk reduction [ARR] 31 percent, 95% CI 13-46 percent) in addition to improving several secondary outcomes including persistent symptoms at 72 hours (23 versus 53 percent with placebo, ARR 30 percent, 95% CI 13-45 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar benefits were noted with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    in the treatment of a first episode of acute pericarditis and in the prevention of post-pericardiotomy syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/8,28\">",
"     8,28",
"    </a>",
"    ]. Subsequently, in a 2012 systematic review and meta-analysis of 795 patients from five randomized trials of colchicine therapy for acute or recurrent pericarditis or prevention of the post-pericardiotomy syndrome, the use of colchicine was associated with a significantly lower risk of developing recurrent pericarditis (RR 0.40, 95% CI 0.30-0.54) without a significantly higher risk of adverse events [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    in addition to an NSAID or as monotherapy for recurrent pericarditis was given a class I recommendation by the 2004 ESC guidelines, which were published before CORE and COPE [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/11\">",
"     11",
"    </a>",
"    ]. The recommended dose was 2",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for one or two days, followed by a maintenance dose of 1",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    Nevertheless, in clinical practice, colchicine alone is not efficacious and should be given as adjunct to another antiinflammatory agent (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , NSAID, or corticosteroid).",
"   </p>",
"   <p>",
"    Treatment of pericarditis and prevention of recurrence is an",
"    <strong>",
"     off label use",
"    </strong>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    . Although low doses of colchicine (0.6 to 1.2 mg per day) have been safe in most patients even when given continuously over decades, there are uncommon (&lt;1 percent) possible side effects to be considered (eg, bone marrow suppression, hepatotoxicity, and muscle toxicity) beyond the well-known gastrointestinal side effects (5 to 10 percent). Chronic kidney disease leading to increased plasma colchicine levels appears to be the major risk factor for side effects. Patient compliance may improve if a loading dose is avoided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoid therapy should generally be avoided in patients with recurrent pericarditis given the potential adverse effects and risk of increasing the likelihood of further recurrences. Glucocorticoid therapy is a double-edged sword in patients with pericardial diseases; it may have specific but rare indications, but it should be a last resort. Glucocorticoids may be considered for patients who fail NSAID and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    therapy; those with definite rheumatologic disease; presumed autoimmune etiology; and intolerance or contraindications to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or NSAIDs (eg, pregnant patients). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/25/20886?source=see_link\">",
"     \"Management of pericardial diseases during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If glucocorticoids are used, the potential benefit and harms should be discussed with the patient and possible preventive measures instituted. The patient should also be informed that some investigators believe that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    may, in some cases, perpetuate rather than abolish recurrences and that, once a glucocorticoid course has been completed, the aim is to taper the dose and finally discontinue prednisone therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/8,10,21-24\">",
"     8,10,21-24",
"    </a>",
"    ]. Common mistakes are to use too low a dose and, more often, to taper the dose too rapidly [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=see_link\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172171\">",
"    <span class=\"h3\">",
"     Our approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;We use lower doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (0.2 to",
"    <span class=\"nowrap\">",
"     0.5mg/Kg/day;",
"    </span>",
"    ie, 25mg for the average patient) maintained for four weeks until symptom resolution and C-reactive protein normalization. Slow tapering is recommended and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    can be added [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/31\">",
"     31",
"    </a>",
"    ]. Toward the end of the taper, antiinflammatory treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or another NSAID should be introduced. In our experience, the need for other immunosuppressive treatments is rare following this therapeutic scheme.",
"   </p>",
"   <p>",
"    Support for this approach comes from an observational study of 100 patients with recurrent pericarditis (51 treated with high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    <span class=\"nowrap\">",
"     1.0mg/Kg/day",
"    </span>",
"    and 49 treated with prednisone 0.2 to 0.5",
"    <span class=\"nowrap\">",
"     mg/Kg/day,",
"    </span>",
"    with similar baseline features in the two groups). After adjustment for potential confounders, only high doses of prednisone were associated with severe side effects, recurrences, and hospitalizations (hazard ratio, 3.61; 95% confidence interval, 1.96 to 6.63) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If symptoms recur, every effort should be made not to increase or reinstitute glucocorticoids, but instead control symptoms with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or an NSAID. Guidelines recommend osteoporosis prevention when using these drugs, an issue often neglected in clinical practice. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=see_link\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172207\">",
"    <span class=\"h3\">",
"     Steroid dependent pericarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite guidelines and reviews recommending limiting the use of glucocorticoids in pericarditis, glucocorticoid use is widespread. There is only one retrospective study to support a regimen of high-dose glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/30\">",
"     30",
"    </a>",
"    ]. This study reported outcomes in 12 patients who had experienced a total of 39 relapses over the preceding 14 months despite therapy with low doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    . Patients were treated with a three-month course of high-dose prednisone (1 to 1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for 4 weeks then gradually withdrawn). Following this aggressive regimen, one patient had a single relapse over the ensuing 42 months. When the prednisone taper was started, all patients received a five-month course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (1.6",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    until glucocorticoid withdrawal, and then 0.8",
"    <span class=\"nowrap\">",
"     g/day).",
"    </span>",
"    Three patients had severe glucocorticoid-induced side effects and were switched to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Following this study, reviews and European guidelines on the management of pericardial diseases have recommended the use of high doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (1.0 to 1.5",
"    <span class=\"nowrap\">",
"     mg/Kg/day)",
"    </span>",
"    for one month or more for patients with recurrent pericarditis, when corticosteroids are required [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/11\">",
"     11",
"    </a>",
"    ]. Unfortunately, this treatment is often quickly tapered because of fear of possible side effects. Relapses requiring prolonged glucocorticoid treatment are common with associated severe side effects.",
"   </p>",
"   <p>",
"    Thus, one of the most troublesome issues in pericardial diseases is how to manage a patient with recurrent pericarditis and glucocorticoid-dependence. When high doses are administered, side effects are not uncommon and may result in the early withdrawal of the drugs. Low to moderate doses of corticosteroids (ie,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    0.2 to",
"    <span class=\"nowrap\">",
"     0.5mg/kg/day)",
"    </span>",
"    are commonly prescribed to treat serositis in patients with rheumatologic conditions. In our experience, the use of these lower doses may be a way to minimize side effects while maintaining efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/33\">",
"     33",
"    </a>",
"    ]. Slow prednisone tapering is critical and a proposed tapering scheme follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Daily dose &gt;50 mg &ndash; tapered 10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      every one to two weeks",
"     </li>",
"     <li>",
"      Daily dose 25-50 mg &ndash; tapered 5 to 10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      every one to two weeks",
"     </li>",
"     <li>",
"      Daily dose 15-25 mg &ndash; tapered 2.5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      every two to four weeks",
"     </li>",
"     <li>",
"      Daily dose &lt;15 mg &ndash; tapered 1.25 to 2.5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      every two to six weeks",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Each decrement in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    dose should proceed only if the patient is asymptomatic and C-reactive protein is normal, particularly for doses lower than 25",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6270729\">",
"    <span class=\"h3\">",
"     Combined steroid therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For persistent cases, it is important to try to control symptoms with a combination of traditional therapies including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or an NSAID,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    , and a corticosteroid before resorting to more complex, and often hazardous, immunosuppressive therapies. This is especially important for idiopathic cases with an overall good prognosis, where more aggressive approaches are not warranted. Additional ways to control more severe episodes of chest pain may include IV administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    or NSAID, corticosteroid IV bolus, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/50/42792?source=see_link\">",
"     tramadol",
"    </a>",
"    oral administration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Intrapericardial steroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrapericardial glucocorticoid therapy to achieve high local glucocorticoid concentrations may maintain efficacy while minimizing systemic toxicity. The 2004 ESC guidelines concluded that the weight of evidence or opinion was in favor of usefulness or efficacy of intrapericardial glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/11\">",
"     11",
"    </a>",
"    ]. However, in our view, the utility of such an approach requires further investigation.",
"   </p>",
"   <p>",
"    In a review of 84 patients with recurrent or persistent autoreactive pericarditis with effusion, pericardiocentesis with antibiotic prophylaxis was followed by intrapericardial administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    (300 to 600",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    given in 100 mL of isotonic saline at body temperature) as a single injection and then removed at 24 hours; maintenance therapy consisted of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    (0.5 mg three times daily) for six months [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This regimen led to symptomatic improvement and prevented recurrence in 90 percent of patients at three months and 84 percent at one year. Most relapses were asymptomatic and only symptomatic large effusions were retreated, using the higher",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    dose. Transient cushingoid symptoms developed in 13 and 30 percent of patients given 300 and 600",
"    <span class=\"nowrap\">",
"     mg/m2,",
"    </span>",
"    respectively. The authors recommended beginning with the 300 mg dose of triamcinolone with appropriate analgesia at the time of instillation, followed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    therapy for six months.",
"   </p>",
"   <p>",
"    There are technical considerations that may limit the usefulness of intrapericardial therapy. If the patient has a large or moderate sized pericardial effusion, intrapericardial therapy is straightforward. This is usually accomplished via intrapericardial catheter following drainage of the pericardial effusion. If the patient has a small, or no pericardial effusion, pericardioscopy or the PerDUCER technique must be available to utilize this form of treatment. Neither procedure is readily available in the United States, and they are currently performed in few specialized European centers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4025?source=see_link&amp;anchor=H13#H13\">",
"     \"Diagnosis and treatment of pericardial effusion\", section on 'Pericardial fluid analysis and biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Other immune therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who do not tolerate",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or the small number who do not respond adequately, another immunosuppressive agent should be added. The ESC guidelines recommend",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    (75 to 100",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/30\">",
"     30",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     Mycophenolate",
"    </a>",
"    may be less toxic but evidence of efficacy in this setting is only anecdotal.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    therapy and intravenous immune globulin have also been effective but data are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/12,19,34\">",
"     12,19,34",
"    </a>",
"    ]. Case reports also suggest that the interleukin receptor blocker",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/294?source=see_link\">",
"     anakinra",
"    </a>",
"    may be effective in reducing symptoms and signs of inflammation in patients with refractory symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/35-37\">",
"     35-37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Recurrent pain without objective evidence of disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A difficult management problem is presented by the patient who reports recurrence of pain, but in whom no clinical or laboratory evidence of pericarditis can be elicited. This problem is most likely to occur in more chronic cases in which numerous recurrences have been suppressed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/23\">",
"     23",
"    </a>",
"    ]. The cause of this phenomenon is unknown, but the need to withhold prednisone is clear. The problem is further complicated by the fact that, in some patients who are having a recurrence, pain precedes objective evidence of pericarditis.",
"   </p>",
"   <p>",
"    It is necessary to explain to the patient that the pain may not be a manifestation of recurrence. However, patients who have experienced frequent recurrences may be hard to convince; as a result, it is important to carefully describe the clinical dilemma and explain the need to stop",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , or not to start a new course of glucocorticoid therapy.",
"   </p>",
"   <p>",
"    Our approach is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The pain is treated by simple analgesic remedies, and steroids are avoided for several days.",
"     </li>",
"     <li>",
"      The patient is then reexamined and ECG, chest radiograph, echocardiogram, sedimentation rate (ESR), C-reactive protein (CRP), and white blood cell count are obtained [",
"      <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/4\">",
"       4",
"      </a>",
"      ]. Cardiac magnetic resonance (CMR) imaging with delayed enhancement should be considered if the diagnosis remains uncertain after the above testing as it is highly sensitive for pericardial inflammation. Signs of pericarditis that qualify for establishment of the diagnosis include pericardial rubs, ECG changes, a pericardial effusion, and pericardial inflammation shown by cardiac MRI. An otherwise unexplained elevation in serum CRP is also suggestive of recurrent pericarditis in these patients.",
"     </li>",
"     <li>",
"      If signs of pericarditis are present, another course of treatment as outlined above is begun.",
"     </li>",
"     <li>",
"      If there is no objective evidence of pericarditis, the patient is told that, although the pain is indistinguishable from that of previous episodes, pericarditis is no longer present and that it is not known why the pain has recurred. Pain management should be initiated at this point.",
"     </li>",
"     <li>",
"      Pain management begins with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      , but more potent analgesics can be given, if necessary. If the pain is still not controlled, the patient is referred to a pain clinic with periodic monitoring for pericarditis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Role of pericardiectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In our view, and in the view of most cardiologists specializing in the care of pericardial disease, pericardiectomy is an imperfect and unpredictable therapy which should be considered as therapy for recurrent pericarditis only after a thorough trial of medical therapy has been unsuccessful.",
"   </p>",
"   <p>",
"    In persons with ongoing symptoms and relapses in spite of medical therapy, however, pericardiectomy does appear to be a safe and frequently effective treatment option. The largest reported cohort of patients with chronic recurrent pericarditis (mean six to seven relapses) included 184 patients treated at a single referral center from 1994 through 2005, with significant baseline differences noted between the two groups (patients in the surgical group had had more relapses [6.9 versus 5.5 in the medical treatment group] and were more likely to have been taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    or steroids) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/38\">",
"     38",
"    </a>",
"    ]. Surgery for pericardiectomy appears to be safe, with no deaths and only two major complications (one stroke, one episode of bleeding requiring re-operation) in the immediate post-operative period and no significant difference in all-cause mortality over an average follow-up of 5.5 years. Additionally, patients treated with surgical pericardiectomy had significantly fewer relapses (9 versus 29 percent in the medical treatment group).",
"   </p>",
"   <p>",
"    The 2004 ESC guidelines gave a class IIa recommendation (weight of evidence or opinion is in favor of usefulness or efficacy) to pericardiectomy only for frequent and highly symptomatic recurrences resistant to medical treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11177/abstract/11\">",
"     11",
"    </a>",
"    ]. In our practice, there are two indications for pericardiectomy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If more than one recurrence is accompanied by cardiac tamponade, which is uncommon.",
"     </li>",
"     <li>",
"      If a recurrence is principally manifested by persistent pain despite an intensive trial with medical treatment and evidence of serious glucocorticoid toxicity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A major concern is the prospect of impaired wound healing when sternotomy or thoracotomy is performed in patients who have had a prolonged exposure to high doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    . Thus, when the decision for pericardiectomy is made, every effort should be made to maintain the patient on a glucocorticoid-free regimen for ONE YEAR preoperatively, although glucocorticoid use is not an absolute contraindication to proceeding with pericardiectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/14/38113?source=see_link\">",
"       \"Patient information: Pericarditis in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (See",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?11/53/12115?source=see_link\">",
"       \"Patient information: Pericarditis (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7605049\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recurrent pericarditis, which occurs in up to one-third of patients following a previous attack of acute pericarditis, is characterized by the reappearance of signs (pericardial rubs, electrocardiogram changes, pericardial",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pleural effusion) and symptoms (chest pain) after treatment of the original episode. The diagnosis of recurrent pericarditis is based on the presence of recurrent chest pain plus objective evidence of disease activity (",
"      <a class=\"graphic graphic_table graphicRef64302 \" href=\"UTD.htm?24/22/24939\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In most instances, recurrent pericarditis is considered to be an autoimmune process, although viral infections may play a role (chronic infection, reinfection, new viral infection). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recurrent pericarditis occurs at a variable time after the initial attack, but usually within 18 months. The number of recurrences and the intervals between them vary considerably among patients, although the majority of patients who develop recurrent pericarditis will have more than one recurrence. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical course'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The preferred treatment of recurrent pericarditis is a combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      or nonsteroidal antiinflammatory drugs (NSAIDs) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      . The high doses of aspirin and NSAIDs used require concomitant gastroprotection (",
"      <a class=\"graphic graphic_table graphicRef50462 \" href=\"UTD.htm?24/48/25355\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Nonsteroidal antiinflammatory drugs'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Colchicine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Glucocorticoid therapy should generally be avoided given the potential adverse effects and higher risk of future recurrences. Glucocorticoids may be considered for patients who fail NSAID and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      therapy; those with definite rheumatologic disease; presumed autoimmune etiology; and intolerance or contraindications to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      or NSAIDs (eg, pregnant patients). If glucocorticoids are given, they should be used at low to moderate doses with very gradual tapering over months. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pericardiectomy is an imperfect and unpredictable therapy and should be considered as therapy for recurrent pericarditis only after a thorough trial of medical therapy has been unsuccessful. However, pericardiectomy does appear to be a safe and frequently effective treatment option in persons with ongoing symptoms and relapses in spite of medical therapy. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Role of pericardiectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While most patients with recurrent pericarditis are well between attacks, and the overall prognosis in patients with idiopathic recurrent pericarditis is excellent, a minority of patients have a more persistent or chronic course. However, severe complications are uncommon even with multiple recurrences, and the prevalence of pericardial effusion and cardiac tamponade decreases with subsequent episodes. In addition, constrictive pericarditis is not common following idiopathic recurrent pericarditis. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical course'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Role of pericardiectomy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11177/abstract/1\">",
"      Shabetai R. Recurrent pericarditis: recent advances and remaining questions. Circulation 2005; 112:1921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11177/abstract/2\">",
"      Robinson J, Brigden W. Recurrent pericarditis. Br Med J 1968; 2:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11177/abstract/3\">",
"      Fowler NO. Recurrent pericarditis. Cardiol Clin 1990; 8:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11177/abstract/4\">",
"      Fowler NO, Harbin AD 3rd. Recurrent acute pericarditis: follow-up study of 31 patients. J Am Coll Cardiol 1986; 7:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11177/abstract/5\">",
"      Troughton RW, Asher CR, Klein AL. Pericarditis. Lancet 2004; 363:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11177/abstract/6\">",
"      Imazio M, Demichelis B, Parrini I, et al. Day-hospital treatment of acute pericarditis: a management program for outpatient therapy. J Am Coll Cardiol 2004; 43:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11177/abstract/7\">",
"      Maisch B, Risti AD, Pankuweit S. Intrapericardial treatment of autoreactive pericardial effusion with triamcinolone; the way to avoid side effects of systemic corticosteroid therapy. Eur Heart J 2002; 23:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11177/abstract/8\">",
"      Imazio M, Bobbio M, Cecchi E, et al. Colchicine in addition to conventional therapy for acute pericarditis: results of the COlchicine for acute PEricarditis (COPE) trial. Circulation 2005; 112:2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11177/abstract/9\">",
"      Spodick DH. Intrapericardial treatment of persistent autoreactive pericarditis/myopericarditis and pericardial effusion. Eur Heart J 2002; 23:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11177/abstract/10\">",
"      Imazio M, Bobbio M, Cecchi E, et al. Colchicine as first-choice therapy for recurrent pericarditis: results of the CORE (COlchicine for REcurrent pericarditis) trial. Arch Intern Med 2005; 165:1987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11177/abstract/11\">",
"      Maisch B, Seferovi PM, Risti AD, et al. Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task force on the diagnosis and management of pericardial diseases of the European society of cardiology. Eur Heart J 2004; 25:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11177/abstract/12\">",
"      Brucato A, Brambilla G, Moreo A, et al. Long-term outcomes in difficult-to-treat patients with recurrent pericarditis. Am J Cardiol 2006; 98:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11177/abstract/13\">",
"      Maisch B. Recurrent pericarditis: mysterious or not so mysterious? Eur Heart J 2005; 26:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11177/abstract/14\">",
"      Pankuweit S, W&auml;dlich A, Meyer E, et al. Cytokine activation in pericardial fluids in different forms of pericarditis. Herz 2000; 25:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11177/abstract/15\">",
"      DeLine JM, Cable DG. Clustering of recurrent pericarditis with effusion and constriction in a family. Mayo Clin Proc 2002; 77:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11177/abstract/16\">",
"      Imazio M, Demichelis B, Parrini I, et al. Management, risk factors, and outcomes in recurrent pericarditis. Am J Cardiol 2005; 96:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11177/abstract/17\">",
"      Soler-Soler J, Sagrist&agrave;-Sauleda J, Permanyer-Miralda G. Relapsing pericarditis. Heart 2004; 90:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11177/abstract/18\">",
"      Brucato A, Brambilla G, Adler Y, et al. Therapy for recurrent acute pericarditis: a rheumatological solution? Clin Exp Rheumatol 2006; 24:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11177/abstract/19\">",
"      Raatikka M, Pelkonen PM, Karjalainen J, Jokinen EV. Recurrent pericarditis in children and adolescents: report of 15 cases. J Am Coll Cardiol 2003; 42:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11177/abstract/20\">",
"      Imazio M, Brucato A, Adler Y, et al. Prognosis of idiopathic recurrent pericarditis as determined from previously published reports. Am J Cardiol 2007; 100:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11177/abstract/21\">",
"      Lange RA, Hillis LD. Clinical practice. Acute pericarditis. N Engl J Med 2004; 351:2195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11177/abstract/22\">",
"      Artom G, Koren-Morag N, Spodick DH, et al. Pretreatment with corticosteroids attenuates the efficacy of colchicine in preventing recurrent pericarditis: a multi-centre all-case analysis. Eur Heart J 2005; 26:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11177/abstract/23\">",
"      Imazio M, Demichelis B, Parrini I, et al. Recurrent pain without objective evidence of disease in patients with previous idiopathic or viral acute pericarditis. Am J Cardiol 2004; 94:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11177/abstract/24\">",
"      Godeau P, Derrida JP, Bletry O, Herreman G. [Recurrent acute pericarditis and corticoid dependence. Apropos of 10 cases]. Sem Hop 1975; 51:2393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11177/abstract/25\">",
"      Imazio M, Spodick DH, Brucato A, et al. Controversial issues in the management of pericardial diseases. Circulation 2010; 121:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11177/abstract/26\">",
"      Imazio M, Brucato A, Mayosi BM, et al. Medical therapy of pericardial diseases: part I: idiopathic and infectious pericarditis. J Cardiovasc Med (Hagerstown) 2010; 11:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11177/abstract/27\">",
"      Imazio M, Brucato A, Cemin R, et al. Colchicine for recurrent pericarditis (CORP): a randomized trial. Ann Intern Med 2011; 155:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11177/abstract/28\">",
"      Imazio M, Trinchero R, Brucato A, et al. COlchicine for the Prevention of the Post-pericardiotomy Syndrome (COPPS): a multicentre, randomized, double-blind, placebo-controlled trial. Eur Heart J 2010; 31:2749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11177/abstract/29\">",
"      Imazio M, Brucato A, Forno D, et al. Efficacy and safety of colchicine for pericarditis prevention. Systematic review and meta-analysis. Heart 2012; 98:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11177/abstract/30\">",
"      Marcolongo R, Russo R, Laveder F, et al. Immunosuppressive therapy prevents recurrent pericarditis. J Am Coll Cardiol 1995; 26:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11177/abstract/31\">",
"      Markel G, Imazio M, Brucato A, Adler Y. Colchicine for the prevention of recurrent pericarditis. Isr Med Assoc J 2008; 10:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11177/abstract/32\">",
"      Imazio M, Brucato A, Cumetti D, et al. Corticosteroids for recurrent pericarditis: high versus low doses: a nonrandomized observation. Circulation 2008; 118:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11177/abstract/33\">",
"      Imazio M, Brucato A, Trinchero R, et al. Corticosteroid therapy for pericarditis: a double-edged sword. Nat Clin Pract Cardiovasc Med 2008; 5:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11177/abstract/34\">",
"      Peterlana D, Puccetti A, Simeoni S, et al. Efficacy of intravenous immunoglobulin in chronic idiopathic pericarditis: report of four cases. Clin Rheumatol 2005; 24:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11177/abstract/35\">",
"      Scardapane A, Brucato A, Chiarelli F, Breda L. Efficacy of an Interleukin-1&beta; Receptor Antagonist (Anakinra) in Idiopathic Recurrent Pericarditis. Pediatr Cardiol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11177/abstract/36\">",
"      Vassilopoulos D, Lazaros G, Tsioufis C, et al. Successful treatment of adult patients with idiopathic recurrent pericarditis with an interleukin-1 receptor antagonist (anakinra). Int J Cardiol 2012; 160:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11177/abstract/37\">",
"      Picco P, Brisca G, Traverso F, et al. Successful treatment of idiopathic recurrent pericarditis in children with interleukin-1beta receptor antagonist (anakinra): an unrecognized autoinflammatory disease? Arthritis Rheum 2009; 60:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11177/abstract/38\">",
"      Khandaker MH, Schaff HV, Greason KL, et al. Pericardiectomy vs medical management in patients with relapsing pericarditis. Mayo Clin Proc 2012; 87:1062.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4944 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-84F2B57B49-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_58_11177=[""].join("\n");
var outline_f10_58_11177=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7605049\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL COURSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Predictors of recurrence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Communication with the patient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Nonsteroidal antiinflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Colchicine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H172171\">",
"      - Our approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H172207\">",
"      - Steroid dependent pericarditis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6270729\">",
"      - Combined steroid therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Intrapericardial steroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Other immune therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Recurrent pain without objective evidence of disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Role of pericardiectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7605049\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/4944\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4944|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/22/24939\" title=\"table 1\">",
"      Diagnostic criteria for acute and recurrent pericarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/48/25355\" title=\"table 2\">",
"      NSAID dosing in recurrent pericarditis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=related_link\">",
"      Cardiac tamponade",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37625?source=related_link\">",
"      Clinical presentation and diagnostic evaluation of acute pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/12/12490?source=related_link\">",
"      Constrictive pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4025?source=related_link\">",
"      Diagnosis and treatment of pericardial effusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/25/20886?source=related_link\">",
"      Management of pericardial diseases during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=related_link\">",
"      NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24648?source=related_link\">",
"      Nonselective NSAIDs: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/53/12115?source=related_link\">",
"      Patient information: Pericarditis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/14/38113?source=related_link\">",
"      Patient information: Pericarditis in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/31/24055?source=related_link\">",
"      Pericardial complications of myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=related_link\">",
"      Prevention and treatment of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/44/713?source=related_link\">",
"      Treatment of acute pericarditis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_58_11178="Diagnosis and treatment of invasive pulmonary aspergillosis in HIV-infected patients";
var content_f10_58_11178=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis and treatment of invasive pulmonary aspergillosis in HIV-infected patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/58/11178/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/58/11178/contributors\">",
"     John W Baddley, MD, MSPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/58/11178/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/58/11178/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/58/11178/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/58/11178/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/58/11178/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H18396793\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the years prior to the introduction of potent antiretroviral therapy (ART), invasive aspergillosis was an important cause of morbidity and mortality in patients with AIDS. In the present day, this infection is now rarely seen in this patient population except among those with advanced immunosuppression.",
"   </p>",
"   <p>",
"    This topic will address the diagnosis and treatment of aspergillosis. The epidemiology and clinical manifestations of aspergillosis in HIV-infected patients are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/28/35270?source=see_link\">",
"     \"Epidemiology and clinical manifestations of pulmonary aspergillosis and invasive disease in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9541090\">",
"    <span class=\"h1\">",
"     GENERAL BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Invasive aspergillosis is an uncommon, but life-threatening, opportunistic infection in patients with AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11178/abstract/1\">",
"     1",
"    </a>",
"    ]. Invasive pulmonary aspergillosis is characterized by fungal invasion into the lung parenchyma with pneumonia, with or without dissemination to other organ systems, including the central nervous system, heart, kidney, and sinuses. The majority of patients present with fever, dyspnea and cough [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11178/abstract/1\">",
"     1",
"    </a>",
"    ]. A wide spectrum of radiographic changes can be seen, including cavitary lesions, focal alveolar infiltrates, or diffuse interstitial infiltrates. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=see_link\">",
"     \"Epidemiology and clinical manifestations of invasive aspergillosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9541157\">",
"    <span class=\"h1\">",
"     APPROACH TO DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of invasive aspergillosis rests upon:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Isolation of the organism",
"     </li>",
"     <li>",
"      The probability that the organism is the cause of disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The first diagnostic dilemma is to differentiate colonization from invasive infection. It is estimated that a person may inhale between 20 and 2000 Aspergillus spores per day, which can lead to fungal colonization [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11178/abstract/2\">",
"     2",
"    </a>",
"    ]. However, only a small percentage of patients will develop invasive disease, as demonstrated on histopathology.",
"   </p>",
"   <p>",
"    The probability that the isolation of Aspergillus species represents a true pathogen is a function of the host&rsquo;s risk factors for disease and whether the patient has a compatible clinical presentation. Host risk factors for the development of invasive disease include a CD4 cell count of &lt;50",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ,",
"    </span>",
"    neutropenia, or recent use of corticosteroids. Other risk factors for invasive infection include a history of underlying lung disease or opportunistic infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/28/35270?source=see_link\">",
"     \"Epidemiology and clinical manifestations of pulmonary aspergillosis and invasive disease in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1439438\">",
"    <span class=\"h1\">",
"     DISEASE CLASSIFICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an effort to standardize the definitions of invasive fungal infections for clinical research, the Invasive Fungal Infections Cooperative Group (IFICG) of the European Organization for Research and Treatment of Cancer (EORTC) and the Mycoses Study Group (MSG) of the",
"    <span class=\"nowrap\">",
"     NIH/National",
"    </span>",
"    Institute of Allergy and Infectious Diseases (NIAID) joined efforts to create guidelines for the diagnosis of invasive aspergillosis to aid researchers [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11178/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. A classification system was formed to designate disease as either &ldquo;proven&rdquo;, &ldquo;probable&rdquo; or &ldquo;possible&rdquo; invasive aspergillosis, as follows:",
"   </p>",
"   <p>",
"    Demonstration of hyphal elements invading tissues (from a biopsy of any affected site, such as the lung or skin) represents a &ldquo;proven&rdquo; diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11178/abstract/4\">",
"     4",
"    </a>",
"    ]. Isolation of the organism by culture in a patient with a compatible clinical syndrome represents &ldquo;probable&rdquo; disease. Identification of markers of the organism (eg, antigen detection) with a compatible syndrome would represent &ldquo;possible&rdquo; disease.",
"   </p>",
"   <p>",
"    These disease classifications have been a useful clinical tool for healthcare providers, although it is important to understand that they were written to aid clinical research and are focused on immunocompromised patients with malignancy or with a history of organ transplantation. The utility of these guidelines in HIV-infected patients is unclear since the sensitivity and specificity of molecular diagnostic assays in HIV-infected patients with aspergillosis has not been established (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9541246\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC ASSAYS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assays commonly employed for the diagnosis of aspergillosis in the immunocompromised host include culture, histology, and antigen detection methods. However, in contrast to patients with a history of hematologic malignancy or transplantation, antigen detection methods (eg, galactomannan and beta-D-glucan) have not been thoroughly studied in HIV patients with invasive aspergillosis; thus, the role of these molecular diagnostic assays is uncertain in this patient population [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11178/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At present, fungal cultures with histopathology are the foundation for the diagnosis of invasive disease in the HIV-infected host.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18396808\">",
"    <span class=\"h2\">",
"     Culture and histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Culture and histology offer complimentary information and both should be obtained whenever feasible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9541284\">",
"    <span class=\"h3\">",
"     Culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aspergillus species grow rapidly and may be visible within several days of incubation, even on standard blood agar; however, colonies of aspergillus may be overgrown by bacteria in standard media. In contrast, pure colonies of aspergillus grow well on fungal media, including Sabouraud&rsquo;s dextrose agar or Potato dextrose agar. Thus, these special media are preferred, and should be requested, for Aspergillus isolation.",
"   </p>",
"   <p>",
"    However, a culture alone may be only indicative of colonization; histopathology is required to document tissue invasion [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11178/abstract/5\">",
"     5",
"    </a>",
"    ]. If a biopsy is not possible because of clinical limitations (eg, thrombocytopenia), a positive culture in the appropriate clinical setting (advanced immunosuppression with pulmonary infiltrates) without isolation of any other potential pathogens can be considered a &ldquo;probable&rdquo; diagnosis of aspergillosis. (See",
"    <a class=\"local\" href=\"#H1439438\">",
"     'Disease classifications'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9541277\">",
"    <span class=\"h3\">",
"     Histopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Special stains for histopathologic examination of aspergillus species (eg, periodic acid-Schiff or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/57/3989?source=see_link\">",
"     methenamine",
"    </a>",
"    silver stain) demonstrate septate hyphae with characteristic acute angle branching (",
"    <a class=\"graphic graphic_picture graphicRef70889 \" href=\"UTD.htm?28/20/28998\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11178/abstract/6\">",
"     6",
"    </a>",
"    ]. Invasive disease is diagnosed when these hyphae are found to be eroding into tissue structures.",
"   </p>",
"   <p>",
"    However, histopathology alone does not confirm a diagnosis of invasive aspergillosis since there are other fungal pathogens that have similar morphology; a culture is required for confirmation of aspergillus as the implicated pathogen. When a culture is positive for aspergillus and histopathology reveals tissue invasion, a &ldquo;definitive&rdquo; diagnosis of aspergillosis can be made [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11178/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18396815\">",
"    <span class=\"h2\">",
"     Antigen detection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Galactomannan is a cell-wall polysaccharide specific to aspergillus species that is released with the growth of hyphae and is detectable in serum or other body fluids (eg, bronchoalveolar lavage specimens) during invasive infection. In a meta-analysis of the use of galactomannan in approximately 4000 patients with either hematologic malignancy or history of organ transplantation, the overall sensitivity and specificity was 71 and 89 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11178/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3913?source=see_link\">",
"     \"Diagnosis of invasive aspergillosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, there are scant data using this technology among HIV-infected patients so the sensitivity and specificity in this population is unknown. Furthermore, the sensitivity of this diagnostic assay declines in patients who are already taking mould-active therapy.",
"   </p>",
"   <p>",
"    False-positive aspergillus test results have been reported among patients taking certain antibiotics (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24216?source=see_link\">",
"     piperacillin-tazobactam",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11178/abstract/8\">",
"     8",
"    </a>",
"    ]. In addition, false-positive test results have been reported for other fungal organisms (eg, Penicillium, Histoplasma), which can be important diagnostic considerations in patients with advanced AIDS, depending on their geographic location or exposure history [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11178/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/63/39924?source=see_link\">",
"     \"Epidemiology and clinical manifestations of histoplasmosis in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/33/33302?source=see_link\">",
"     \"Epidemiology and clinical manifestations of Penicillium marneffei infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18396829\">",
"    <span class=\"h2\">",
"     Beta-D-glucan",
"    </span>",
"    &nbsp;&mdash;&nbsp;1,3-Beta-D-glucan, a cell wall component of many fungi, is detected by the beta-D-glucan assay. This assay is not specific for Aspergillus species, and can be positive in patients with a variety of invasive fungal infections, including candidiasis and Pneumocystis jirovecii (formerly P. carinii). In fact, beta-d-glucan has been reported to be a supportive non-invasive adjunctive test for Pneumocystis pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11178/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In various studies evaluating beta-D-glucan assays for the diagnosis of invasive fungal infections, the sensitivity has ranged from 55 to 95 percent and the specificity has ranged from 77 to 96 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11178/abstract/12-18\">",
"     12-18",
"    </a>",
"    ]. Likely reasons for the wide ranging differences in sensitivity and specificities include variations in the commercial diagnostic assays used, study participants who were enrolled, and study design. Most of these studies did not evaluate the utility of the test in the HIV-infected host with suspected invasive aspergillosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18396836\">",
"    <span class=\"h2\">",
"     Polymerase chain reaction (PCR) assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;DNA detection using PCR techniques has been explored in patients with invasive aspergillosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11178/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. Due to lack of standardization of this test, there are no clear guidelines on the best use of this assay; furthermore, there are scant data on the use of this assay in HIV-infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11178/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9541259\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the best means of determining invasive infection is by microscopic examination of tissue. Diagnosis requires documentation of characteristic acute angle branching septate hyphae invading the surrounding tissue on biopsy specimens. However, because some other moulds will appear similar on histopathologic examination, culture confirmation is required. Without a culture, the differential diagnosis of acute angle branching septate hyphae includes scedosporium and fusarium, which uncommonly cause infection in patients with advanced AIDS.",
"   </p>",
"   <p>",
"    Scedosporiosis and aspergillosis have very similar clinical manifestations. However, in disseminated Fusarium infection, which is associated with prolonged neutropenia, target skin lesions are often seen, while skin involvement in disseminated aspergillosis is uncommon.",
"   </p>",
"   <p>",
"    Corticosteroid use and diabetes are associated with increased risk of mucormycosis; however, this mould infection is a rare cause of pulmonary disease among AIDS patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11178/abstract/22,23\">",
"     22,23",
"    </a>",
"    ] and the hyphae of this pathogen are distinguished by their nonseptate morphology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3080073\">",
"    <span class=\"h1\">",
"     AVAILABLE ANTIFUNGAL AGENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11819968\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following antifungal compounds have in vitro and in vivo activity against Aspergillus [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11178/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Polyenes, including standard",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      deoxycholate and related lipid formulations",
"     </li>",
"     <li>",
"      Triazoles, including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"       posaconazole",
"      </a>",
"     </li>",
"     <li>",
"      Echinocandins, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"       caspofungin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"       micafungin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"       anidulafungin",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Historically,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    has been the most commonly used drug for invasive aspergillosis; however,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    is now recommended as primary therapy for invasive aspergillosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11178/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1439495\">",
"     'Clinical efficacy and safety data'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1439487\">",
"    <span class=\"h2\">",
"     Triazoles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Triazole agents with good activity against aspergillus species include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    .",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     Itraconazole",
"    </a>",
"    is not used due to poor efficacy and tolerability [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11178/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     Fluconazole",
"    </a>",
"    has no activity against aspergillus species.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18396857\">",
"    <span class=\"h3\">",
"     Voriconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     Voriconazole",
"    </a>",
"    has enhanced activity against Aspergillus species and has become the primary therapy of choice for the treatment of invasive aspergillosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11178/abstract/24,25,29\">",
"     24,25,29",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3080638\">",
"     'Approach to treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1439495\">",
"    <span class=\"h4\">",
"     Clinical efficacy and safety data",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     Voriconazole",
"    </a>",
"    was compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate in a randomized trial involving 277 patients with confirmed or probable aspergillosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11178/abstract/25\">",
"     25",
"    </a>",
"    ]. The vast majority of patients had a history of hematologic malignancy or transplantation; only 13 patients (5 percent) had underlying HIV infection. The treating clinician was allowed to switch the patient to another antifungal agent for drug intolerance or clinical failure. At 12 weeks of follow-up, patients assigned to voriconazole had generally more favorable outcomes compared with those who were assigned to the amphotericin B arm, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A greater likelihood of having a complete or partial clinical response (53 versus 32 percent)",
"     </li>",
"     <li>",
"      A lower mortality rate (29 versus 42 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    arm also had a lower likelihood of being reassigned to a different antifungal agent because of intolerance or poor response (36 versus 80 percent). The most common symptom was transient vision changes. However, the relative efficacy and safety of voriconazole compared with lipid formulations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    is unknown since no comparative studies have been published.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1439748\">",
"    <span class=\"h3\">",
"     Pharmacology and dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     Voriconazole",
"    </a>",
"    is well distributed throughout the body as demonstrated by its large volume of distribution [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11178/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Voriconazole may also have a role in the setting of CNS disease, because of its excellent penetration into brain abscess fluid and cerebrospinal fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11178/abstract/32-34\">",
"     32-34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     Voriconazole",
"    </a>",
"    is available in both intravenous and oral formulations [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11178/abstract/25,32,35\">",
"     25,32,35",
"    </a>",
"    ]. The recommended dosing regimen is 6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV twice a day on day one followed by 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV twice daily. When the patient is able to take oral medications, one can consider switching to the oral formulation (ie, 200 mg twice daily) on an empty stomach for maximal absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11178/abstract/30\">",
"     30",
"    </a>",
"    ]. Dosing of voriconazole in the setting of renal or hepatic insufficiency and other pharmacokinetic data are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link\">",
"     \"Pharmacology of azoles\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serum drug concentrations should be monitored approximately one week into therapy with target trough and peak serum concentrations of &gt;1",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    and &lt;5.5",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    to maximize efficacy and minimize toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11178/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18396964\">",
"     'Therapeutic drug monitoring'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     Voriconazole",
"    </a>",
"    is an inhibitor of cytochrome P450 3A4; thus, drug interactions should be anticipated and managed. This is a particularly important issue for potential drug-drug interactions with HIV antiretroviral medications. (See",
"    <a class=\"local\" href=\"#H11820778\">",
"     'Drug interactions'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18396864\">",
"    <span class=\"h3\">",
"     Posaconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     Posaconazole",
"    </a>",
"    is an extended spectrum azole with excellent in vitro activity against aspergillus species with supportive animal data suggesting efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11178/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no controlled trials that have compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    for the treatment of invasive aspergillosis and no direct comparative trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    and posaconazole for this indication. In one observational study of 107 immunocompromised patients (including 10 with HIV infection), the use of posaconazole as salvage therapy was associated with clinical improvement in 42 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11178/abstract/26\">",
"     26",
"    </a>",
"    ]. Adverse events attributed to posaconazole occurred in 47 percent of patients, including nausea (12 percent) and vomiting (5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11178/abstract/26\">",
"     26",
"    </a>",
"    ]. The trial results are limited by its observational nature, the heterogeneity of prior drug exposure, and the limited prior use of voriconazole (five patients only).",
"   </p>",
"   <p>",
"    The dose for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    for salvage therapy is 800 mg of oral suspension in two or four divided doses. No intravenous formulation is available. Steady-steady-state levels may not be achieved for up to a week, impacting use as initial therapy for invasive aspergillosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11178/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18396878\">",
"    <span class=\"h2\">",
"     Polyenes",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26294672\">",
"    <span class=\"h2\">",
"     Conventional amphotericin B",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate (conventional amphotericin) has been the most frequently used drug for invasive aspergillosis, but is no longer a first-line agent because of decreased efficacy and increased toxicity when compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11178/abstract/24,25,38,39\">",
"     24,25,38,39",
"    </a>",
"    ]. Studies of immunocompromised patients with proven or probable aspergillosis suggest high rates of mortality (26 to 65 percent) among immunocompromised patients treated with amphotericin B therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11178/abstract/38,40\">",
"     38,40",
"    </a>",
"    ]. Disadvantages of amphotericin B include the requirement for a central venous catheter, common infusion-related adverse events, and dose-related nephrotoxicity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/5/38998?source=see_link\">",
"     \"Amphotericin B nephrotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the HIV-infected patient with definitive aspergillosis,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    is only administered if drug-drug interactions with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    are unavoidable or if the patient cannot tolerate voriconazole.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18396894\">",
"    <span class=\"h3\">",
"     Lipid formulations of amphotericin B",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared to conventional",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    , lipid formulations are similar in efficacy for aspergillosis with overall improved safety profiles, particularly with regard to nephrotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11178/abstract/38\">",
"     38",
"    </a>",
"    ]. Thus, when amphotericin B is selected rather than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    , lipid formulations are often administered [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11178/abstract/24\">",
"     24",
"    </a>",
"    ], especially in the patient with preexisting renal insufficiency, or among those who are taking medications with potential nephrotoxic effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1439755\">",
"    <span class=\"h4\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lipid formulations most commonly used are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/27/18871?source=see_link\">",
"     Amphotericin B lipid complex",
"    </a>",
"    (Ablecet&reg;, ABLC), which is dosed 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily; or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    (Ambisome&reg;, L-AMB), dosed 3 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily. Higher doses of Ambisome do not appear to result in improved responses in patients with invasive aspergillosis (ie, 10",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11178/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another lipid formulation,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    colloidal dispersion (Amphotec&reg;) is rarely used because infusion-related reactions are similar in frequency as with conventional amphotericin B [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11178/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15001?source=see_link\">",
"     \"Pharmacology of amphotericin B\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18396901\">",
"    <span class=\"h2\">",
"     Echinocandins",
"    </span>",
"    &nbsp;&mdash;&nbsp;The echinocandins are active against Aspergillus species. Commercially available agents include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    (Cancidas&reg;);",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"     micafungin",
"    </a>",
"    (Mycamine&reg;); and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"     anidulafungin",
"    </a>",
"    (Eraxis&reg;).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18396908\">",
"    <span class=\"h3\">",
"     Caspofungin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     Caspofungin",
"    </a>",
"    was demonstrated to be effective as salvage therapy among 93 immunocompromised patients with invasive aspergillosis who were refractory or intolerant of prior antifungal therapy with overall complete and partial clinical improvement in 45 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11178/abstract/41\">",
"     41",
"    </a>",
"    ]. The study results are limited by its observational design and the heterogeneity of prior drug exposure in terms of agents and duration. Furthermore, the comparative azole was",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    , which is no longer used due to limited efficacy and frequency of adverse events.",
"   </p>",
"   <p>",
"    The recommended dose for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    is a 70 mg IV loading dose once, followed by 50 mg IV daily. Caspofungin is not recommended as primary therapy for invasive aspergillosis, as few data describing use in this setting are available [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11178/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3080561\">",
"    <span class=\"h3\">",
"     Micafungin and anidulafungin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"     Micafungin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"     anidulafungin",
"    </a>",
"    have similar activity and safety profiles when compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    . However, clinical data regarding use of these agents for treatment of invasive aspergillosis are limited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3080638\">",
"    <span class=\"h1\">",
"     APPROACH TO TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;When invasive aspergillosis is definitively diagnosed or suspected, rapid initiation of therapy is indicated since this infection is associated with high rates of mortality approaching 75 percent among HIV-infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11178/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The choice of drug depends on two main issues: whether the diagnosis is definitive and whether drug-drug interactions or toxicities are anticipated.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the patient with a &ldquo;definitive&rdquo; diagnosis of invasive aspergillosis, we recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      , which has demonstrated efficacy and safety in immunocompromised patients with hematologic malignancy and among those with a history of organ transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?10/58/11178/abstract/24,45-50\">",
"       24,45-50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      When the diagnosis is unclear (eg, possible or probable disease), but a mould infection is suspected (eg, hyphae are present but culture results are not available), use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      as initial therapy should be considered pending further diagnostic data, since",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      is not active against the agents of mucormycosis. The presence of nonseptate hyphae would support a possible diagnosis of mucormycosis, while septate hyphae would support a diagnosis of aspergillosis as the most likely pathogen in a patient with AIDS. In the latter case, voriconazole could be considered pending culture confirmation.",
"     </li>",
"     <li>",
"      All triazoles have significant drug interactions with several antiretroviral medications; thus, a careful review of potential drug-drug interactions is indicated. Since the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      constrains the choice of antiretroviral medications due to drug-drug interactions,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      may be necessary if an appropriate regimen cannot be constructed due to additional concerns, such as HIV drug resistance. (See",
"      <a class=\"local\" href=\"#H11820778\">",
"       'Drug interactions'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11819941\">",
"    <span class=\"h2\">",
"     Combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of combination antifungal therapy with different antifungal targets for invasive aspergillosis is appealing theoretically, but no data are available from prospective, controlled clinical trials to support such an approach for either initial or salvage therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11178/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. In vitro and animal data also suggest antagonism between triazoles and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11178/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When combination therapy is used in clinical practice, an echinocandin is often administered, despite supportive clinical trial data [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11178/abstract/45,54,55\">",
"     45,54,55",
"    </a>",
"    ]. For the treatment of invasive aspergillosis in HIV-infected patients, combination therapy is not routinely recommended at this time pending further data.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11820725\">",
"    <span class=\"h1\">",
"     DURATION OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antifungal therapy should continue until clinical symptoms have resolved, and radiographic findings have improved or have stabilized. For most patients with invasive aspergillosis, treatment for at least 6 to 12 weeks is necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11178/abstract/24\">",
"     24",
"    </a>",
"    ]. Longer therapy may be required for patients with multiorgan disease or CNS involvement.",
"   </p>",
"   <p>",
"    Patients should be monitored by evaluating clinical signs and symptoms and radiographic findings. Although monitoring with aspergillus galactomannan testing may be helpful in some immunosuppressed populations, this approach has not yet been studied in HIV-infected patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11820778\">",
"    <span class=\"h1\">",
"     DRUG INTERACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The triazoles (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    ) undergo cytochrome P-450 hepatic metabolism, and all are inhibitors of cytochrome P-450 3A metabolism, so careful assessment for possible drug interactions is recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link\">",
"     \"Pharmacology of azoles\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Relevant to HIV-infected patients, the triazoles have a potential interaction with protease inhibitors (PIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs), as discussed below. Interactions with the integrase inhibitor,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    , or with nucleoside reverse transcriptase inhibitors, have not been described and would not be anticipated based on their metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11178/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11820818\">",
"    <span class=\"h2\">",
"     Voriconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    is also an inhibitor of cytochrome P450 3A4, drug interactions are a concern, particularly when selecting antiretroviral medications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11820825\">",
"    <span class=\"h3\">",
"     Effect on voriconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protease inhibitors, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    , lopinavir,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/11/44217?source=see_link\">",
"     fosamprenavir",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/33/19992?source=see_link\">",
"     tipranavir",
"    </a>",
"    must be avoided since these agents will likely lead to significantly decreased concentrations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11178/abstract/56-58\">",
"     56-58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sometimes",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    is used for pharmacokinetic boosting of the parent protease inhibitor. Whether low-dose ritonavir (eg, 100 mg daily) can be considered is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11178/abstract/56\">",
"     56",
"    </a>",
"    ]; therapeutic drug monitoring of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    would be prudent if ritonavir boosting is needed since drug-drug interactions with voriconazole have been described. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40458?source=see_link&amp;anchor=H32#H32\">",
"     \"HIV protease inhibitors\", section on 'Pharmacokinetic boosting'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nonnucleoside reverse transcriptase inhibitors (NNRTIs) may also decrease the serum concentrations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    ; this has been noted specifically for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11178/abstract/59\">",
"     59",
"    </a>",
"    ]. One study in healthy volunteers suggested that doses of voriconazole should be increased to 400 mg daily and efavirenz dosing should be decreased to 300 mg daily to adjust for drug-drug interactions [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11178/abstract/59\">",
"     59",
"    </a>",
"    ]. Similar drug-drug interactions would be expected for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    , although there are no data regarding this combination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11820832\">",
"    <span class=\"h3\">",
"     Effect on antiretroviral medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;In vitro studies suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    may increase the drug concentrations of the PIs, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/11/44217?source=see_link\">",
"     fosamprenavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/62/19433?source=see_link\">",
"     nelfinavir",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3482?source=see_link\">",
"     saquinavir",
"    </a>",
"    and NNRTIs, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13320?source=see_link\">",
"     etravirine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11178/abstract/56\">",
"     56",
"    </a>",
"    ]. One study in healthy volunteers found no effect of voriconazole on unboosted",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11178/abstract/60\">",
"     60",
"    </a>",
"    ]; however, this drug is no longer considered a first-line agent for the treatment of HIV infection.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     Voriconazole",
"    </a>",
"    also interacts with the entry inhibitor,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/45/20182?source=see_link\">",
"     maraviroc",
"    </a>",
"    ; dose reduction of maraviroc is advised in patients taking a strong cyp3A inhibitor (eg, 150 mg maraviroc twice daily).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11820839\">",
"    <span class=\"h2\">",
"     Caspofungin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The NNRTIs (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    ) and the PI,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/62/19433?source=see_link\">",
"     nelfinavir",
"    </a>",
"    , may decrease the concentration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    . ART should be adjusted to include two NRTIs plus a PI, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    , when feasible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the patient must be treated with an",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    -containing regimen, increasing the dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    to 70 mg IV daily should be considered in patients who are not clinically responding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11820858\">",
"    <span class=\"h2\">",
"     Antiretroviral medications without known drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;When possible, it is optimal to use an ART regimen that includes drugs that are not metabolized via the cytochrome P450 pathway, if HIV drug resistance is not a concern. Such medications include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Integrase strand inhibitors (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"       raltegravir",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Nucleoside reverse transcriptase inhibitors (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"       emtricitabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"       abacavir",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1271491\">",
"    <span class=\"h1\">",
"     SELECTION OF ANTIRETROVIRAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Taking all of the caveats about drug-drug interactions above into consideration, potential regimens in a patient on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       Tenofovir",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"       emtricitabine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"       raltegravir",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       Tenofovir",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"       emtricitabine",
"      </a>",
"      plus unboosted",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/36/25161?source=see_link\">",
"       indinavir",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both of these options need to take into consideration HIV drug resistance patterns. The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    -containing regimen is preferred when feasible since unboosted",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    is no longer considered a preferred agent for the treatment of HIV.",
"   </p>",
"   <p>",
"    If",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    -containing ART is not feasible due to issues related to HIV drug resistance, the following regimens could be considered with therapeutic drug monitoring and increased dosing of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    to 400 mg twice daily:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       Tenofovir",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"       emtricitabine",
"      </a>",
"      plus dose-reduced",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      (ie, 300 mg daily)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    is administered, then the dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    must be increased to 400 mg twice daily. Therapeutic drug monitoring is discussed below. (See",
"    <a class=\"local\" href=\"#H18396964\">",
"     'Therapeutic drug monitoring'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    If",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    has been selected for antifungal therapy, other potential nephrotoxic agents should be avoided. Thus,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    may be preferred over",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    in some patients with invasive aspergillosis. If the patient&rsquo;s pretreatment HIV RNA level is &gt;100,000",
"    <span class=\"nowrap\">",
"     copies/mL,",
"    </span>",
"    tenofovir may still be preferred due to greater clinical efficacy in this patient subset.",
"   </p>",
"   <p>",
"    The selection of antiretroviral therapy for the treatment of HIV infection is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1271368\">",
"    <span class=\"h1\">",
"     WHEN TO START ANTIRETROVIRAL THERAPY IN PATIENTS WITH ASPERGILLOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the recommended primary therapy for invasive aspergillosis,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    , has important interactions with certain antiretroviral medications. Careful selection must be made in constructing an appropriate regimen for a treatment-naive patient or adjusting the current regimen in a patient who is already on treatment.",
"   </p>",
"   <p>",
"    In patients with AIDS, potent antiretroviral therapy (ART) leads to restoration of T cell immunity, which is an important mediator of defense against fungal infections [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11178/abstract/40\">",
"     40",
"    </a>",
"    ]. Thus, ART is considered an important adjunct to antifungal therapy.",
"   </p>",
"   <p>",
"    The timing of when to initiate ART relative to antifungal therapy is unknown in the treatment-naive patient. This is an issue of considerable importance in other infections, such as tuberculosis, where a delay of ART for more than two weeks can be associated with significant morbidity and mortality in the HIV-infected patient with a CD4 cell count of &lt;50",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </span>",
"   </p>",
"   <p>",
"    However, immune recovery can also lead to inflammatory complications. The term \"immune reconstitution inflammatory syndrome\" (IRIS) describes a collection of inflammatory disorders associated with paradoxical worsening of preexisting infectious processes following the initiation of potent ART [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11178/abstract/61-66\">",
"     61-66",
"    </a>",
"    ]. If immune function improves rapidly following the commencement of ART, systemic or local inflammatory reactions may occur at the site or sites of the preexisting infection. This inflammatory reaction is usually self-limited, especially if the preexisting infection is effectively treated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=see_link\">",
"     \"Immune reconstitution inflammatory syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To date, IRIS has been reported rarely in the setting of HIV infection and aspergillosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11178/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. Thus, antiretroviral therapy should not be withheld during antifungal therapy for invasive aspergillosis due to concerns regarding IRIS. The initiation of ART may be considered within two weeks of starting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    to first assess for adverse events related to this antifungal agent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H11#H11\">",
"     \"Pharmacology of azoles\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18396964\">",
"    <span class=\"h1\">",
"     THERAPEUTIC DRUG MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assays are currently available for monitoring serum concentrations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    ; the role of therapeutic drug monitoring for the treatment of invasive aspergillosis has not yet been established [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11178/abstract/69\">",
"     69",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"   </p>",
"   <p>",
"    However, it may be helpful to monitor serum trough concentrations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    (or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    ) routinely in HIV-infected patients during therapy if a potential drug-drug interaction is present or if the patient is at risk of malabsorption (eg, history of chronic diarrhea). A target minimal serum concentration for voriconazole is 1 to 2",
"    <span class=\"nowrap\">",
"     mcg/mL;",
"    </span>",
"    for posaconazole, the target range is 0.5 to 1.5",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/58/11178/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. Therapeutic drug monitoring may be considered for certain NNRTIs, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9541141\">",
"    <span class=\"h1\">",
"     MAINTENANCE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance antifungal therapy for aspergillosis is not routinely indicated, particularly if the patient&rsquo;s CD4 cell count has improved significantly (eg, greater than 200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ).",
"    </span>",
"   </p>",
"   <p>",
"    Due to the problematic drug-drug interactions with most antiretroviral medications, discontinuation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    when the patient is clinically improved may be the optimal strategy, which will increase the patient&rsquo;s therapeutic options for HIV care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18396978\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the years prior to the introduction of potent antiretroviral therapy (ART), invasive aspergillosis was an important cause of morbidity and mortality in patients with AIDS. In the present day, this infection is now rarely seen except among untreated HIV-infected patients with advanced immunosuppression. (See",
"      <a class=\"local\" href=\"#H18396793\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Invasive pulmonary aspergillosis is characterized by fungal invasion into lung parenchyma with pneumonia, with or without dissemination to other organ systems, including the central nervous system, heart, kidney, and sinuses. The majority of patients present with fever, dyspnea and cough. (See",
"      <a class=\"local\" href=\"#H9541090\">",
"       'General background'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of invasive aspergillosis in HIV-infected patients is based upon a combination of clinical risks, symptoms and signs, culture, and histopathology. Diagnosis requires documentation of characteristic acute angle branching septate hyphae invading tissue on biopsy specimens with culture confirmation. (See",
"      <a class=\"local\" href=\"#H9541246\">",
"       'Diagnostic assays'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Classes of antifungal agents with in vitro activity against aspergillus species include the triazoles, polyenes, and the echinocandins. In a randomized trial,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      was associated with higher rates of clinical efficacy and overall better tolerability than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      among immunocompromised patients with invasive aspergillosis. The study population mainly included patients with a history of hematologic malignancy or transplantation; only five percent of these patients had HIV infection. (See",
"      <a class=\"local\" href=\"#H3080073\">",
"       'Available antifungal agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the HIV-infected patient with a probable or definitive diagnosis of invasive aspergillosis, we recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The recommended dosing regimen is 6 mg per kilogram intravenously (IV) twice daily on day one, followed by 4 mg per kilogram IV twice daily. (See",
"      <a class=\"local\" href=\"#H3080638\">",
"       'Approach to treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with invasive aspergillosis require treatment for 6 to 12 weeks; longer therapy may be required depending on the patient&rsquo;s clinical response. (See",
"      <a class=\"local\" href=\"#H11820725\">",
"       'Duration of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All triazoles have significant drug interactions with several antiretroviral medications; thus, a careful review of potential drug-drug interactions is indicated. (See",
"      <a class=\"local\" href=\"#H11820778\">",
"       'Drug interactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initiation of ART may be considered within two weeks of starting",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      to first assess for adverse events related to this antifungal agent. When possible, it is optimal to use an antiretroviral therapy regimen that includes drugs that are not metabolized via the cytochrome P450 pathway. Such medications include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"       raltegravir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"       emtricitabine",
"      </a>",
"      . All antiretroviral medication selections must also consider issues related to HIV drug resistance. (See",
"      <a class=\"local\" href=\"#H1271491\">",
"       'Selection of antiretroviral therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antiretroviral therapy is associated with improved immune function and is an important adjunct to antifungal therapy. The initiation of HIV treatment may be considered within approximately two weeks of initiating antifungal therapy. (See",
"      <a class=\"local\" href=\"#H1271368\">",
"       'When to start antiretroviral therapy in patients with aspergillosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Therapeutic drug monitoring should be considered in HIV-infected patients, particularly those taking medications with potential drug-drug interactions. A target blood concentration for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      trough levels is 1 to 2",
"      <span class=\"nowrap\">",
"       mcg/mL.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H18396964\">",
"       'Therapeutic drug monitoring'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/1\">",
"      Mylonakis E, Barlam TF, Flanigan T, Rich JD. Pulmonary aspergillosis and invasive disease in AIDS: review of 342 cases. Chest 1998; 114:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/2\">",
"      Latg&eacute; JP. Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev 1999; 12:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/3\">",
"      Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/4\">",
"      De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46:1813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/5\">",
"      Horvath JA, Dummer S. The use of respiratory-tract cultures in the diagnosis of invasive pulmonary aspergillosis. Am J Med 1996; 100:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/6\">",
"      Stergiopoulou T, Meletiadis J, Roilides E, et al. Host-dependent patterns of tissue injury in invasive pulmonary aspergillosis. Am J Clin Pathol 2007; 127:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/7\">",
"      Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 2006; 42:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/8\">",
"      Boonsarngsuk V, Niyompattama A, Teosirimongkol C, Sriwanichrak K. False-positive serum and bronchoalveolar lavage Aspergillus galactomannan assays caused by different antibiotics. Scand J Infect Dis 2010; 42:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/9\">",
"      Narreddy S, Chandrasekar PH. False-positive Aspergillus galactomannan (GM) assay in histoplasmosis. J Infect 2008; 56:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/10\">",
"      Desmet S, Van Wijngaerden E, Maertens J, et al. Serum (1-3)-beta-D-glucan as a tool for diagnosis of Pneumocystis jirovecii pneumonia in patients with human immunodeficiency virus infection or hematological malignancy. J Clin Microbiol 2009; 47:3871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/11\">",
"      Del Palacio A, Llenas-Garc&iacute;a J, Soledad Cu&eacute;tara M, et al. Serum (1--&gt;3) beta-D-Glucan as a noninvasive adjunct marker for the diagnosis and follow-up of pneumocystis jiroveci pneumonia in patients with HIV infection. Clin Infect Dis 2010; 50:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/12\">",
"      Odabasi Z, Mattiuzzi G, Estey E, et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004; 39:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/13\">",
"      Marty FM, Koo S. Role of (1--&gt;3)-beta-D-glucan in the diagnosis of invasive aspergillosis. Med Mycol 2009; 47 Suppl 1:S233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/14\">",
"      Pickering JW, Sant HW, Bowles CA, et al. Evaluation of a (1-&gt;3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 2005; 43:5957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/15\">",
"      Kawazu M, Kanda Y, Nannya Y, et al. Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan, and a (1--&gt;3)-beta-D-glucan test in weekly screening for invasive aspergillosis in patients with hematological disorders. J Clin Microbiol 2004; 42:2733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/16\">",
"      Obayashi T, Negishi K, Suzuki T, Funata N. Reappraisal of the serum (1--&gt;3)-beta-D-glucan assay for the diagnosis of invasive fungal infections--a study based on autopsy cases from 6 years. Clin Infect Dis 2008; 46:1864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/17\">",
"      Ostrosky-Zeichner L, Alexander BD, Kett DH, et al. Multicenter clinical evaluation of the (1--&gt;3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005; 41:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/18\">",
"      Koo S, Bryar JM, Page JH, et al. Diagnostic performance of the (1--&gt;3)-beta-D-glucan assay for invasive fungal disease. Clin Infect Dis 2009; 49:1650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/19\">",
"      Cuenca-Estrella M, Meije Y, Diaz-Pedroche C, et al. Value of serial quantification of fungal DNA by a real-time PCR-based technique for early diagnosis of invasive Aspergillosis in patients with febrile neutropenia. J Clin Microbiol 2009; 47:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/20\">",
"      Suarez F, Lortholary O, Buland S, et al. Detection of circulating Aspergillus fumigatus DNA by real-time PCR assay of large serum volumes improves early diagnosis of invasive aspergillosis in high-risk adult patients under hematologic surveillance. J Clin Microbiol 2008; 46:3772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/21\">",
"      White PL, Bretagne S, Klingspor L, et al. Aspergillus PCR: one step closer to standardization. J Clin Microbiol 2010; 48:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/22\">",
"      Virally ML, Riveline JP, Virally J, et al. Pulmonary mucormycosis in a diabetic patient with HIV. Diabetes Care 2002; 25:2105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/23\">",
"      Davies SF, Sarosi GA. Fungal pulmonary complications. Clin Chest Med 1996; 17:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/24\">",
"      Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/25\">",
"      Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/26\">",
"      Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007; 44:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/27\">",
"      Denning DW, Lee JY, Hostetler JS, et al. NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis. Am J Med 1994; 97:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/28\">",
"      Caillot D, Bassaris H, McGeer A, et al. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin Infect Dis 2001; 33:e83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/29\">",
"      Segal BH. Aspergillosis. N Engl J Med 2009; 360:1870.",
"     </a>",
"    </li>",
"    <li>",
"     Vfend&reg; package insert. Roerig, a Division of Pfizer, Inc. New York, NY, 2008. file://media.pfizer.com/files/products/uspi_vfend.pdf (Accessed on November 12, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/31\">",
"      Weiler S, Fiegl D, MacFarland R, et al. Human tissue distribution of voriconazole. Antimicrob Agents Chemother 2011; 55:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/32\">",
"      Schwartz S, Ruhnke M, Ribaud P, et al. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 2005; 106:2641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/33\">",
"      Hidron AI, Gongora MC, Anderson AM, Diazgranados CA. Prolonged survival of a patient with AIDS and central nervous system aspergillosis. Med Mycol 2009; 47:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/34\">",
"      Schwartz S, Thiel E. Cerebral aspergillosis: tissue penetration is the key. Med Mycol 2009; 47 Suppl 1:S387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/35\">",
"      Imhof A, Balajee SA, Fredricks DN, et al. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004; 39:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/36\">",
"      Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/37\">",
"      Howard SJ, Lestner JM, Sharp A, et al. Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy. J Infect Dis 2011; 203:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/38\">",
"      Bowden R, Chandrasekar P, White MH, et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002; 35:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/39\">",
"      Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007; 44:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/40\">",
"      Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) 2000; 79:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/41\">",
"      Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39:1563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/42\">",
"      Herbrecht R, Maertens J, Baila L, et al. Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study. Bone Marrow Transplant 2010; 45:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/43\">",
"      Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/44\">",
"      Holding KJ, Dworkin MS, Wan PC, et al. Aspergillosis among people infected with human immunodeficiency virus: incidence and survival. Adult and Adolescent Spectrum of HIV Disease Project. Clin Infect Dis 2000; 31:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/45\">",
"      Upton A, Kirby KA, Carpenter P, et al. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007; 44:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/46\">",
"      Segal BH, Walsh TJ. Current approaches to diagnosis and treatment of invasive aspergillosis. Am J Respir Crit Care Med 2006; 173:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/47\">",
"      Patterson TF, Boucher HW, Herbrecht R, et al. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome. Clin Infect Dis 2005; 41:1448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/48\">",
"      B&ouml;hme A, Ruhnke M, Buchheidt D, et al. Treatment of fungal infections in hematology and oncology--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003; 82 Suppl 2:S133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/49\">",
"      Talbot GH, Bradley J, Edwards JE Jr, et al. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 2006; 42:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/50\">",
"      Spanakis EK, Aperis G, Mylonakis E. New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage. Clin Infect Dis 2006; 43:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/51\">",
"      Marr KA, Boeckh M, Carter RA, et al. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004; 39:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/52\">",
"      Baddley JW, Pappas PG. Antifungal combination therapy: clinical potential. Drugs 2005; 65:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/53\">",
"      Meletiadis J, Petraitis V, Petraitiene R, et al. Triazole-polyene antagonism in experimental invasive pulmonary aspergillosis: in vitro and in vivo correlation. J Infect Dis 2006; 194:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/54\">",
"      Baddley JW, Andes DR, Marr KA, et al. Factors associated with mortality in transplant patients with invasive aspergillosis. Clin Infect Dis 2010; 50:1559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/55\">",
"      Neofytos D, Horn D, Anaissie E, et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 2009; 48:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/56\">",
"      Yakiwchuk EM, Foisy MM, Hughes CA. Complexity of interactions between voriconazole and antiretroviral agents. Ann Pharmacother 2008; 42:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/57\">",
"      Liu P, Foster G, Gandelman K, et al. Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects. Antimicrob Agents Chemother 2007; 51:3617.",
"     </a>",
"    </li>",
"    <li>",
"     Zhu L, Uy J,. Bruggemann R, et al. CYP2C19 genotype-dependent pharmacokinetic drug interaction between voriconazole and ritonavir boosted atazanavir in healthy subjects. 13th International Workshop on Clinical Pharmacology of HIV Therapy, April 16-18, 2012, Barcelona. Abstract O_08. (Accessed on April 17, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/59\">",
"      Damle B, LaBadie R, Crownover P, Glue P. Pharmacokinetic interactions of efavirenz and voriconazole in healthy volunteers. Br J Clin Pharmacol 2008; 65:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/60\">",
"      Purkins L, Wood N, Kleinermans D, Love ER. No clinically significant pharmacokinetic interactions between voriconazole and indinavir in healthy volunteers. Br J Clin Pharmacol 2003; 56 Suppl 1:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/61\">",
"      DeSimone JA, Pomerantz RJ, Babinchak TJ. Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy. Ann Intern Med 2000; 133:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/62\">",
"      French MA, Lenzo N, John M, et al. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med 2000; 1:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/63\">",
"      Shelburne SA 3rd, Hamill RJ, Rodriguez-Barradas MC, et al. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore) 2002; 81:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/64\">",
"      Michelet C, Arvieux C, Fran&ccedil;ois C, et al. Opportunistic infections occurring during highly active antiretroviral treatment. AIDS 1998; 12:1815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/65\">",
"      Hirsch HH, Kaufmann G, Sendi P, Battegay M. Immune reconstitution in HIV-infected patients. Clin Infect Dis 2004; 38:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/66\">",
"      Shelburne SA, Montes M, Hamill RJ. Immune reconstitution inflammatory syndrome: more answers, more questions. J Antimicrob Chemother 2006; 57:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/67\">",
"      Hasse B, Strebel B, Thurnheer R, et al. Chronic necrotizing pulmonary aspergillosis after tuberculosis in an HIV-positive woman: an unusual immune reconstitution phenomenon? AIDS 2005; 19:2179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/68\">",
"      Sambatakou H, Denning DW. Invasive pulmonary aspergillosis transformed into fatal mucous impaction by immune reconstitution in an AIDS patient. Eur J Clin Microbiol Infect Dis 2005; 24:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/69\">",
"      Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother 2009; 53:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/58/11178/abstract/70\">",
"      Dodds Ashley ES, Lewis R, Lewis JS, et al. Pharmacology of Systemic Antifungal Agents. Clin Infect Dis 2006; 43 Suppl 1:S28.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13967 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-197.136.42.3-AA8FF843F1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_58_11178=[""].join("\n");
var outline_f10_58_11178=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18396978\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18396793\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9541090\">",
"      GENERAL BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9541157\">",
"      APPROACH TO DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1439438\">",
"      DISEASE CLASSIFICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9541246\">",
"      DIAGNOSTIC ASSAYS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18396808\">",
"      Culture and histology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9541284\">",
"      - Culture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9541277\">",
"      - Histopathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18396815\">",
"      Antigen detection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18396829\">",
"      Beta-D-glucan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18396836\">",
"      Polymerase chain reaction (PCR) assays",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9541259\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3080073\">",
"      AVAILABLE ANTIFUNGAL AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11819968\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1439487\">",
"      Triazoles",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18396857\">",
"      - Voriconazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1439495\">",
"      Clinical efficacy and safety data",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1439748\">",
"      - Pharmacology and dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18396864\">",
"      - Posaconazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18396878\">",
"      Polyenes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26294672\">",
"      Conventional amphotericin B",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18396894\">",
"      - Lipid formulations of amphotericin B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1439755\">",
"      Dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18396901\">",
"      Echinocandins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18396908\">",
"      - Caspofungin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3080561\">",
"      - Micafungin and anidulafungin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3080638\">",
"      APPROACH TO TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11819941\">",
"      Combination therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11820725\">",
"      DURATION OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11820778\">",
"      DRUG INTERACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11820818\">",
"      Voriconazole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11820825\">",
"      - Effect on voriconazole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11820832\">",
"      - Effect on antiretroviral medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11820839\">",
"      Caspofungin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11820858\">",
"      Antiretroviral medications without known drug interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1271491\">",
"      SELECTION OF ANTIRETROVIRAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1271368\">",
"      WHEN TO START ANTIRETROVIRAL THERAPY IN PATIENTS WITH ASPERGILLOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18396964\">",
"      THERAPEUTIC DRUG MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9541141\">",
"      MAINTENANCE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18396978\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/13967\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/13967|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/20/28998\" title=\"picture 1\">",
"      Histopathology Aspergillus spp",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/5/38998?source=related_link\">",
"      Amphotericin B nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3913?source=related_link\">",
"      Diagnosis of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/33/33302?source=related_link\">",
"      Epidemiology and clinical manifestations of Penicillium marneffei infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/63/39924?source=related_link\">",
"      Epidemiology and clinical manifestations of histoplasmosis in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=related_link\">",
"      Epidemiology and clinical manifestations of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/28/35270?source=related_link\">",
"      Epidemiology and clinical manifestations of pulmonary aspergillosis and invasive disease in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40458?source=related_link\">",
"      HIV protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=related_link\">",
"      Immune reconstitution inflammatory syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15001?source=related_link\">",
"      Pharmacology of amphotericin B",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=related_link\">",
"      Pharmacology of azoles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=related_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_58_11179="Oral rx renal abscess";
var content_f10_58_11179=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F58686&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F58686&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Oral antibiotic therapy of renal or perinephric abscess",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Antibiotic",
"      </td>",
"      <td class=\"subtitle1\">",
"       Dose, interval",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Levofloxacin",
"      </td>",
"      <td>",
"       500 to 750 mg every 24 hours",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ciprofloxacin",
"      </td>",
"      <td>",
"       500 mg every 12 hours",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ciprofloxacin XR",
"      </td>",
"      <td>",
"       1000 mg every 24 hours",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Trimethoprim-sulfamethoxazole",
"      </td>",
"      <td>",
"       1 double strength tablet every 12 hours",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Trimethoprim",
"      </td>",
"      <td>",
"       100 mg every 12 hours or 200 mg every 24 hours",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cefpodoxime",
"      </td>",
"      <td>",
"       200 mg every 12 hours",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cefixime",
"      </td>",
"      <td>",
"       200 mg every 12 hours or 400 mg every 24 hours",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Amoxicillin*",
"      </td>",
"      <td>",
"       250-500 mg every 8 hours or 500-875 mg every 12 hours",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * For treatment of known or suspected enterococcus.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_58_11179=[""].join("\n");
var outline_f10_58_11179=null;
var title_f10_58_11180="Antiarrhythmic drugs to maintain sinus rhythm in AF";
var content_f10_58_11180=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F53499&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F53499&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pooled results of randomized controlled trials of antiarrhythmic drugs for maintenance of sinus rhythm after conversion of atrial fibrillation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Odds ratio versus control (95% CI, number of trials)",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Trials reporting side effect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Sustained ventricular, arrhythmia, percent",
"       </td>",
"       <td class=\"subtitle2\">",
"        Cessation or decreased dose, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amiodarone",
"       </td>",
"       <td>",
"        6.8 (4.0 to 11.4, 2 trials)",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0 to 9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Propafenone",
"       </td>",
"       <td>",
"        3.0 (2.0 to 4, 7, 4 trials)",
"       </td>",
"       <td>",
"        0 to 3",
"       </td>",
"       <td>",
"        3 to 25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Disopyramide",
"       </td>",
"       <td>",
"        2.9 (1.4 to 6.1, 2 trials)",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0 to 55",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sotalol",
"       </td>",
"       <td>",
"        2.5 (1.7 to 3.7, 4 trials)",
"       </td>",
"       <td>",
"        0 to 5",
"       </td>",
"       <td>",
"        5 to 13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flecainide",
"       </td>",
"       <td>",
"        4.3 (1.3 to 14.1, 3 trials)",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0 to 20 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Quinidine",
"       </td>",
"       <td>",
"        2.7 (1.1 to 6.8, 4 trials)",
"       </td>",
"       <td>",
"        0 to 12",
"       </td>",
"       <td>",
"        4 to 58",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Azimilide",
"       </td>",
"       <td>",
"        1.6 (1.2 to 2.2, 1 trial)",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    NOTE: The data in this table cannot be directly applied to clinical practice since the choice of drug will vary with a number of factors including the presence or absence of coronary disease or heart failure.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from McNamara RL, Tamariz LJ, Segal JB, Bass EB. Ann Intern Med 2004; 139:1018.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_58_11180=[""].join("\n");
var outline_f10_58_11180=null;
var title_f10_58_11181="FDA approved prosthetic valves";
var content_f10_58_11181=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F50825&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F50825&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    FDA-approved prosthetic heart valves",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Type",
"       </td>",
"       <td class=\"subtitle1\">",
"        Manufacturer",
"       </td>",
"       <td class=\"subtitle1\">",
"        Model",
"       </td>",
"       <td class=\"subtitle1\">",
"        Year of first clinical use",
"       </td>",
"       <td class=\"subtitle1\">",
"        Implants* (thousands)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\" rowspan=\"1\">",
"        Mechanical",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ball",
"       </td>",
"       <td>",
"        Baxter Edwards",
"       </td>",
"       <td>",
"        Starr-Edwards",
"       </td>",
"       <td>",
"        1965",
"       </td>",
"       <td>",
"        200",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\" rowspan=\"3\">",
"        Disk",
"       </td>",
"       <td>",
"        Medtronic",
"       </td>",
"       <td>",
"        Medtronic Hall",
"       </td>",
"       <td>",
"        1977",
"       </td>",
"       <td>",
"        178",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medical Inc.",
"       </td>",
"       <td>",
"        Omniscience",
"       </td>",
"       <td>",
"        1978",
"       </td>",
"       <td>",
"        48",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alliance",
"       </td>",
"       <td>",
"        Monostrut",
"       </td>",
"       <td>",
"        1982",
"       </td>",
"       <td>",
"        94",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\" rowspan=\"3\">",
"        Bileaflet",
"       </td>",
"       <td>",
"        St. Jude",
"       </td>",
"       <td>",
"        St. Jude",
"       </td>",
"       <td>",
"        1977",
"       </td>",
"       <td>",
"        580",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Baxter Edwards",
"       </td>",
"       <td>",
"        Duromedics",
"       </td>",
"       <td>",
"        1982&bull;",
"       </td>",
"       <td>",
"        20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CarboMedics",
"       </td>",
"       <td>",
"        CarboMedics",
"       </td>",
"       <td>",
"        1986",
"       </td>",
"       <td>",
"        110",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\" rowspan=\"1\">",
"        Biological",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\" rowspan=\"6\">",
"        Porcine",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Medtronic",
"       </td>",
"       <td>",
"        Hancock Standard",
"       </td>",
"       <td>",
"        1970&nbsp;&nbsp;&nbsp;&nbsp;",
"       </td>",
"       <td>",
"        177",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hancock MO",
"       </td>",
"       <td>",
"        1978",
"       </td>",
"       <td>",
"        32",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Baxter Edwards",
"       </td>",
"       <td>",
"        CE Standard",
"       </td>",
"       <td>",
"        1971",
"       </td>",
"       <td>",
"        400",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CE SupraAnnular",
"       </td>",
"       <td>",
"        1982",
"       </td>",
"       <td>",
"        45",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        St. Jude",
"       </td>",
"       <td>",
"        Toronto Stentless (TSP)",
"       </td>",
"       <td>",
"        1991",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medtronic",
"       </td>",
"       <td>",
"        Free Style",
"       </td>",
"       <td>",
"        1992",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pericardial",
"       </td>",
"       <td>",
"        Baxter Edwards",
"       </td>",
"       <td>",
"        CE",
"       </td>",
"       <td>",
"        1982",
"       </td>",
"       <td>",
"        35",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\" rowspan=\"2\">",
"        Homograft",
"       </td>",
"       <td>",
"        Noncommercial&Delta;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        1962",
"       </td>",
"       <td>",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cryolife&Delta;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        1984",
"       </td>",
"       <td>",
"        14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Autologous",
"       </td>",
"       <td>",
"        noncommercial&Delta;",
"       </td>",
"       <td>",
"        Pulmonary autograft",
"       </td>",
"       <td>",
"        1967",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MO: modified orifice; CE: Carpentier-Edwards.",
"     <br>",
"      * Approximate number of implants through part or all of 1994.",
"      <br>",
"       &bull;&nbsp;Discontinued in 1988.",
"       <br>",
"        &Delta; Does not require FDA approval for clinical use.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from Bonow RO, Carabello B, de Leon AC, Jr, et al. ACC/AHA Task Force Report. J Am Coll Cardiol 1998; 5:1486.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_58_11181=[""].join("\n");
var outline_f10_58_11181=null;
var title_f10_58_11182="Contents: Adult resuscitation";
var content_f10_58_11182=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?10/42/10926\">",
"       Adult and Pediatric Emergency Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Adult resuscitation",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Adult resuscitation",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Airway management",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/14/36068\">",
"           Advanced emergency airway management in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/34/23079\">",
"           Basic airway management in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/55/25466\">",
"           Devices for difficult emergency airway management in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/48/15111\">",
"           Emergency airway management in acute severe asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/5/13399\">",
"           Emergency airway management in the adult with direct airway trauma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/48/11014\">",
"           Emergency airway management in the geriatric patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/54/20329\">",
"           Emergency airway management in the morbidly obese patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/32/11784\">",
"           Emergency airway management in the patient with elevated ICP",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/35/31288\">",
"           Neuromuscular blocking agents (NMBA) for rapid sequence intubation in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/28/35274\">",
"           Post-cardiac arrest management in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/55/38775\">",
"           Pretreatment agents for rapid sequence intubation in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/55/1912\">",
"           Rapid sequence intubation in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/30/11754\">",
"           Sedation or induction agents for rapid sequence intubation in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/12/22726\">",
"           The decision to intubate",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/7/18552\">",
"           The difficult airway in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/51/18228\">",
"           The failed airway in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cardiovascular",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/33/13850\">",
"           Advanced cardiac life support (ACLS) in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/25/36248\">",
"           Basic life support (BLS) in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/24/4490\">",
"           Evaluation of the survivor of sudden cardiac arrest",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/21/30041\">",
"           Outcome of sudden cardiac arrest",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/24/8585\">",
"           Supportive data for advanced cardiac life support in adults with sudden cardiac arrest",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/39/35448\">",
"           Therapies of uncertain benefit in basic and advanced cardiac life support",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Mechanical ventilation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/25/6554\">",
"           Mechanical ventilation of adults in the emergency department",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Monitoring",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/18/44328\">",
"           Carbon dioxide monitoring (capnography)",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-30DA1692F3-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f10_58_11182=[""].join("\n");
var outline_f10_58_11182=null;
var title_f10_58_11183="AFP levels in AF by GA";
var content_f10_58_11183=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F61170&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F61170&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 492px\">",
"   <div class=\"ttl\">",
"    The approximate relationship between alpha-fetoprotein (AFP) values in amniotic fluid and gestational age",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 472px; height: 352px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data adapted from: Habib, ZA. Maternal Serum alpha-fetoprotein: Its value in antenatal diagnosis of genetic disease and in obstetrical-gynaecological care. Acta Obstet Gynecol Scand 1977;61:1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_58_11183=[""].join("\n");
var outline_f10_58_11183=null;
